The Act Of 29 July 2005 On Counteracting Drug Addiction

Original Language Title: USTAWA z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$20 per month, or Get a Day Pass for only USD$4.99.
Chapter 1 General provisions Article. 1. [range] Act specifies: 1) the rules and procedures in the fight against drug addiction;

2) the tasks and powers of the Government Administration and units of local government and other parties in dealing with violations of the law on the marketing, manufacture, processing, reprocessing and possession of substances whose use can lead to drug abuse;

3) authorities competent to perform: a) of Regulation (EC) of the European Parliament and of the Council No 273/2004 of 11 February 2004 on drug precursors (OJ. EC-L 047 of 18.02.2004), hereinafter referred to as "regulation 273/2004", b) of Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade in drug precursors between the community and third countries (OJ. EC-L 22 of 26.01.2005, p. 1; Oj. In the Polish Special Edition 2005, vol. 48, p. 1), hereinafter referred to as "Regulation 111/2005";

4) penalty for failure to comply with the provisions of the Act and the regulations listed in paragraph 3.

Article. 2. the [Task in dealing with drug addiction] 1. Tackling drug abuse is carried out by the relevant policy development social, economic, educational and health and education, and in particular: 1) the activities of educational, educational, information and prevention;

2) treatment, rehabilitation and reintegration of addicts;

3) reducing health-related harm and social;

4) supervision of substances whose use can lead to drug abuse;

5) combating illegal trading, production, processing, reprocessing and possession of substances whose use can lead to drug abuse;

6) supervision of crops containing substances whose use can lead to addiction.

2. the tasks referred to in paragraph 1. 1 paragraphs 1-3, are financed from its own resources of entities performing tasks in the fight against drug addiction, the resources allocated for the implementation of the programmes referred to in article 1. 48 para. 1 of the law of 27 August 2004 about health care benefits financed from public funds (OJ from 2015.581, as amended), and the national health fund other than those intended for the implementation of health programs.

3. the tasks referred to in paragraph 1. 1 paragraph 4 – 6 are financed from the State budget of the part remaining in the disposal of the competent Ministers.

Article. 3. [the application of the provisions of the Act] provisions of the Act apply to: 1) medicinal products that are narcotic drugs, psychotropic substances or precursors, in terms of unregulated in the Act of 6 September 2001-pharmaceutical law (Journal of laws 2008 No. 45, item 271, as amended);

2) chemical substances and mixtures, which are precursors to the extent unregulated in the rules about chemicals and their mixtures.

Article. 4. [Definitions] used in this Act shall mean: 1) magic mushrooms-mushrooms containing psychotropic substances;

2) the importer is a natural person, a legal person or an entity without legal personality, which makes imports and consists of the customs declaration or on whose behalf the customs declaration is lodged;

3 scientific research unit) unit within the meaning of article 3. 2 section 9 of the Act of 30 April 2010 on the principles of financing of Science (Journal of laws of 2014.1620 and 2015.249 and 1268);

4) hemp-plants of the hemp (Cannabis);

5) hemp-plants of the species cannabis sativa (Cannabis sativa l.), in which aggregate content of delta-9-tetrahydrokannabinolu and dehydrated acid (acid delta-9-THC-2-carboxylic) in flowering or fruiting tops of the plants from which the resin has not been removed, does not exceed 0.20% in terms of dry weight;

6) treatment-treatment of psychiatric and behavioral disorders caused by the use of narcotic drugs or psychotropic substances;

7) replacement therapy is the application, under the treatment of addiction, medicinal products or drugs with agonists to opioid analgesic receptor;

8) mak-the plant of the species poppy (Papaver somniferum l.), also known as poppy garden or condition;

9) mak niskomorfinowy-a plant of the species poppy belonging to varieties, in which the content of morphine in her purse (makówce) without seeds, along with adhering to it stem to a length of 7 cm, less than 0.06% on the principle of morphine and on the dry mass of the listed parts of the plant;

10) poppy seed milk – milk juice pouches (it) poppy seeds;

11) drug addiction – permanent or periodic use for purposes other than medical of narcotic drugs, psychotropic substances, measures or new psychoactive substances, and as a result may arise or dependence on them;

11A) the new psychoactive substance is a substance of natural origin or synthetic, in any physical condition, of the action on the central nervous system, as set out in legislation issued on the basis of art. paragraph 44B. 2;

12) limitation of damages health and social actions aimed at reducing the health and social problems arising out of the use of non-medical purposes of narcotic drugs, psychotropic substances, measures or new psychoactive substances;

13) opium-stężały milk juice pouches (it) poppy seeds;

14) person endangered addiction – a person, in which the team of mental phenomena and environmental impacts is fraught with the likelihood that the dependence of narcotic drugs or psychotropic substances, or occasionally uses of narcotic drugs, psychotropic substances, measures or new psychoactive substances;

15): the person concerned is a person who as a result of the use of narcotic drugs, psychotropic substances, measures or new psychoactive substances or to use them for medical purposes is in a State of dependence on these measures or substance;

16) precursor-a precursor to the drug a substance classified as referred to in article. 2 paragraph a of regulation 273/2004, which a category set out in the annex No. 1 to that regulation;

17) preparation-the medicinal product contains at least one narcotic drug or substance psychotropową or their precursors;

18) producer-entrepreneur producing, processing or producing narcotic drugs, psychotropic substances or precursors;

19) processing-steps leading to the transformation of narcotic drugs, psychotropic substances or precursors to other narcotic drugs, psychotropic substances or precursors or to substances other than narcotics, psychotropic substances or precursors;

20) processing-receiving mixtures of narcotic drugs, psychotropic substances or precursors and broadcast to those or substances as used in medicinal uses;

20A) carriage-any movement of narcotic drugs, psychotropic substances or poppy straw between two Member States by the territory of the Republic of Poland, which begins and ends outside that territory;

21) imports – each input into the customs territory of the European Union of narcotic drugs, psychotropic substances, measures or new psychoactive substances;

22) rehabilitation is a process in which a person with mental disorders caused by the taking of narcotic drugs or psychotropic substances reaches an optimal state of health, mental and social functioning;

23) reintegration – the effect of the actions referred to in article 1. 14-16 and article. 18 of the Act of 13 June 2003 on social employment (OJ of 2011 No. 43, item 225, as amended);

24) poppy straw-pouch (makówkę) poppy seeds without seeds, along with the stem, or individual parts thereof;

25) psychotropic substance is any substance of natural origin or synthetic, acting on the central nervous system, as set out in the list of psychotropic substances in annex No. 2 to the Act;

26) Narcotic-any substance of natural origin or synthetic, acting on the central nervous system, as set out in the list of narcotic drugs Annex No. 1 to act;

27) measure replacement-product containing at least one new psychoactive substance or another substance having a similar effect on the central nervous system, which can be used instead of a narcotic drug or psychotropic substance or in the same purposes as the narcotic drug or psychotropic substance, where the production and the placing on the market is not regulated on the basis of the provisions of the separate; substitute measures shall not apply the provisions of the general product safety;

28) cultivation of opium poppy or cannabis-any cultivation of opium poppy or cannabis regardless of the surface;

29) dependence of narcotic drugs or psychotropic substances is a team of mental phenomena, or somatic resulting from the action of narcotic drugs or psychotropic substances on the human body, characterized by a change in behavior or other psychofizycznymi reactions and the need to use continuously or periodically these measures or substance in order to experience their impact on the psyche or to avoid the consequences caused by their lack of;

30) the use of harmful-the use of psychoactive substance causing injury somatic or mental, including impairment of judgment or dysfunctional behavior that can lead to disability or have unwanted consequences for relationships with other people;

31) use of narcotic, psychotropic substances, substitute or the new psychoactive substance-introduction to the human body narcotic, psychotropic substances, substitute or the new psychoactive substance, regardless of the route of administration;


32) intra-Community supply – the movement of narcotic drugs or psychotropic substances with the territory of the Republic of Poland on the territory of a Member State of the European Union;

33) intra-Community acquisition – the movement of narcotic drugs or psychotropic substances from the territory of a Member State of the European Union on the territory of the Republic of Poland;

34) the placing on the market-share to a third party, whether for a consideration or free of charge, of narcotic drugs, psychotropic substances, precursors, measures or new psychoactive substances;

35) manufacturing steps, which can be obtained narcotic drugs, psychotropic substances, precursors, substitution or new psychoactive substances, purification, extraction of raw materials and semi-finished products, and receive salt these measures or substance;

36) exports-any derivation out of the customs territory of the European Community of narcotic drugs or psychotropic substances;

37) herb of cannabis other than fibrous-any ground part of the plant cannabis (single or mixed), excluding seeds containing more than 0.20% of the sum of delta-9-tetrahydrokannabinolu and dehydrated acid (acid delta-9-THC-2-carboxylic);

38) cannabis resin-resin and other hemp products containing delta-9-tetrahydrocannabinol or other biologically active kannabinole.



Chapter 2 Entities performing tasks in the fight against drug addiction Article. 5. [the authorities performing tasks for counteracting drug addiction] 1. Tasks in the fight against drug addiction, pursue government administrations and local government units to the extent specified in the Act.

2. in dealing with drug addiction are implemented, to the extent specified in the Act, including by: 1) kindergartens, schools, and other organizational units listed in the article. 2 paragraph 3 – 5 and 7 – 9 of the Act of 7 September 1991 on the education system (Journal of laws of 2015.2156 and 2016.35 and 64);

2) higher education;

3) entities and other stakeholders in health care;

4 Polish Army units), the police and border guards;

5) Customs authorities;

6) organizational units of the prison service and correctional establishments and hostels for minors;

7) social assistance centres, district family support centres and regional centres of social policy;

7A) organizational units, foster families and foster care system referred to in article 1. 2. 3 of the Act of 9 June 2011 to support the family and custody system (Journal of laws of 2015.332, as amended), and assistants of the family, foster families and family children's homes;

8) mass media.

3. In carrying out the tasks referred to in article 1. 2. 1, may attend non-governmental organizations and other entities whose activities Office includes tasks belonging to the realm of public tasks in the protection and promotion of health, social assistance, charity, science, education, education and education, physical education, public order and security or to counter social ills, the promotion and organization of volunteering, a design contest, referred to in article 1. 11 (1). 2 of the Act of 24 April 2003 on the activities of public benefit and voluntary service (Journal of laws of 2014 item 1118, as amended), as well as local health professionals, families, addicts, and self-help groups of addicts and their families.

Article. 6. [National Office for counteracting drug addiction] 1. Activities in the field of counteracting drug addiction leads the National Bureau for counteracting drug addiction, hereinafter referred to as "the Office".

2. the Office is a competent Minister responsible budget to health.

3. The tasks of the Office: 1) (repealed) 2) (repealed) 3) tasks in the fight against drug abuse, consisting of entrusting and support to perform their public duties, including the granting of subsidies to finance their implementation on the basis of the mandate the Minister responsible for health;

4) initiating actions to limit the use of narcotic drugs, psychotropic substances, measures or new psychoactive substances;

5) initiate, promote and conduct analysis and research on issues of drug addiction, including the preparation of the assessment of the epidemiological risks drug addiction;

6) initiate work on new legislative solutions to preventing drug addiction;

7) making periodic evaluations of prevention programs, therapeutic, rehabilitative and readaptacyjnych in terms of their effectiveness in the reduction of use of narcotic drugs, psychotropic substances, measures or new psychoactive substances;

8) developing standards for substance abuse prevention and treatment and rehabilitation of addicts;

9) initiating, arranging and conducting of training for those tasks in the fight against drug addiction;

10) provide assistance to professional bodies carrying out tasks in the fight against drug addiction, including local government units, and established educational and informational, research, preventive, curative, rehabilitative and reintegracyjną;

11) cooperation with international organisations active in the fight against drug addiction and loss it caused;

12) conducting national drug information system and monitoring of measures taken to combat drug abuse at national and international level, including: a) the collection, collection, exchange of information and documentation in the field of prevention of drug addiction, covered by statistical research official statistics, and the development and processing of the collected data, b) and initiating research on problems of drugs and drug addiction and the development and sharing of results, c) collection , store and share databases on drugs and drug addiction, d) the formulation of proposals to foster the formation of appropriate to the situation, response strategies to the problem of drug addiction, e) coordinating provincial experts referred to in article 1. 9. 6, f) to collect and share publications on drugs and drug addiction, g) to serve as an observation point (Focal Point) of the European Monitoring Centre for drugs and drug addiction, h) participation in the work of international organisations reporting, and the) cooperation with the European Monitoring Centre for drugs and drug addiction and the European information network on drugs and drug addiction (Reitox), j) developing and publishing an annual report on the State of drug addiction in Poland;

k) (repealed) 13) to undertake interventions in cases of complaints and proposals for counteracting drug addiction issues, addressed to the Office or to the Minister responsible for health;

14) perform other tasks in the fight against drug abuse, commissioned by the Minister responsible for health;

14A) subsidised the costs of training in the field of addiction;

15) support organizational and technical Council for the prevention of drug addiction.

4. the Bureau, by doing the tasks referred to in paragraph 1. 3, works with public administration bodies performing the tasks referred to in article 1. 2, and can create work teams.

5. the tasks referred to in paragraph 1. 3, paragraph 12, the information centre on drugs and drug addiction as an organizational cell Office.

Article. 7. [National Health Program] the basis for action in the fight against drug abuse is a National Health Program, referred to in article 2. 9. 1 of the Act of 11 September 2015. public health (OJ., 1916), hereinafter referred to as the "National Program of health".

Article. 8. (repealed) Article. 9. [the provincial Programme for counteracting drug addiction] 1. The executive body of the local Government of the draft Regional Programme for counteracting drug addiction, hereinafter referred to as the "Regional Programme", taking into account the operational objectives for counteracting drug addiction, referred to in the national health programme. The provincial Program is part of a regional strategy in the field of social policy.

2. Provincial Program adopts the regional province.

3. The Executive Body of the self-government: 1) is responsible for the preparation of the regional project of the program and its implementation and coordination;

2) provide assistance to substantive entities implementing the tasks covered by the Regional programme;

3) interacts with other public administration authorities in the fight against drug addiction.

4. the Regional programme is implemented by the indicated in this program.

5. In order to carry out tasks referred to in paragraph 1. 3, paragraph 1, the executive body of Government may appoint a representative.

6. The Executive Body of Government appoints and dismisses the provincial expert for information on drugs and drug addiction.

7. The tasks of the regional expert for information on drugs and drug addiction, on the territory of the State from the measures referred to in the budget of the local Government of: 1) collect, collection, exchange of information and documentation in the field of prevention of drug addiction, covered by statistical research official statistics, and the development and processing of the collected data;

2) and initiating research on problems of drugs and drug addiction and the development and sharing of the results thereof;

3) collecting, storing and sharing databases on drugs and drug addiction;

4) formulating proposals conducive to the formation of adequate to the situation, response strategies to the problem of drug abuse;

5) collect and share publications on drugs and drug addiction;


6) collection and analysis of information on emerging trends in the use of narcotic drugs, psychotropic substances, or of new psychoactive substances.

Article. 10. [the municipal Programme for counteracting drug addiction] 1. Combating drug addiction belong to the own tasks of the municipality, including: 1) increasing the availability of therapeutic help and rehabilitation for addicts and those at risk of addiction;

2) providing families that are experiencing the problems of drug abuse, legal and psychosocial support;

3) conducting preventive activities, educational information and troubleshooting training drug addiction, in particular for children and young people, including teaching sport and recreational activities for students, as well as activities for infant feeding children participating in extracurricular educational programmes-educational and socjoterapeutycznych;

4) support action taken by the institutions, non-governmental organizations and individuals in order to solve problems of drug abuse;

5) social assistance to individuals and families of addicts affected by poverty and social exclusion and integrating with the local environment of these people with the use of social work and the social contract.

2. the Mayor (Mayor, Mayor of the city) in order to carry out the tasks referred to in paragraph 1. 1, draft Municipal Drug prevention program, hereinafter referred to as the "Municipal", taking into account the operational objectives for counteracting drug addiction, referred to in the national health programme. Communal Program is part of the Municipal Council of social problem-solving strategies.

3. The Municipal Council adopts Programme of the municipality.

4. The municipal programme is implemented by the indicated in this program.

5. In order to carry out tasks referred to in paragraph 1. 1, the Mayor (Mayor, city President) may appoint a representative.

Article. 11. [information on the implementation of The Provincial and Municipal Program] 1. The executive body of the self-government and municipalities shall draw up a report on the implementation in a given year The Provincial and Municipal program and the effects of their implementation, which shall submit to the appropriate sejmikowi of the province or the Council of the municipality, by 31 March of the year following the year to which the report relates.

2. The Executive Body of the self-government and municipalities shall draw up, on the basis of the developed by the Office of survey information with the implementation of the actions to be taken in a given year, resulting from Provincial and Municipal program, and sends it to the Office, no later than 15 April of the year following the year to which it relates.

Article. 12. [the Council for counteracting drug addiction] 1. A Council for counteracting drug addiction, hereinafter referred to as "the Council".

2. the Council is working with the Prime Minister.

3. the Council is a body of coordination and advisory in matters concerning the prevention of drug addiction.

4. the President of the Council of Ministers shall determine by Ordinance, the statutes of the Council, taking into account the specific conditions and mode of its operation, in this way the working parties referred to in article 1. 17. Article. 13. [the Council] 1. The members of the Council shall appoint and dismiss the Prime Minister.

2. the Council shall consist of: 1) Chairman – Secretary or under-Secretary of State in the Office that supports the Minister responsible for health;

2) Deputy President, Secretary or under-Secretary of State in the Office of hosting Minister responsible for Home Affairs;

3) Secretary-Director of the Office;

4) members-Secretary or Undersecretary in the offices that support Ministers: a) Justice, (b)) responsible for the education and upbringing, c) national defence, d) competent for agriculture, e) responsible for social security, f) responsible for public finances – the head of the customs service, g) competent for Foreign Affairs, h) responsible for science, and) responsible for the economy;

5) a member of the local party representative in the Joint Commission of Government and local government, it indicated.

3. the Council shall be convened at least twice a year.

Article. 14. [Appeal Board Member] 1. President of the Council of Ministers of the Council member references due to: 1) resign;

2) participate in the work of the Council;

3) submission of his appeal by the subject, which this person is representative;

4) conviction by a final judgment for an intentional crime or intentional crime tax.

2. In case of cancellation or the death of a member of the Council, the competent entity presents a proposal to appoint another representative as a member of the Council.

Article. 15. [Task of the Council] to the tasks of the Council shall, in particular: 1) monitoring and coordinating activities in the field of the implementation of the State policy in the field of narcotic drugs, psychotropic substances, precursors, measures or new psychoactive substances;

2) to the Minister responsible for health in matters relating to the creation, changes and additions to the national strategies and plans to counter problems caused by the rotation and use of narcotic drugs, psychotropic substances and precursors;

3) monitor information about the implementation of the national strategies and action plans;

4) monitoring of the implementation of the national programme for Health in terms of actions on counteracting drug addiction;

5) recommending organisational as regards counteracting drug addiction;

6) interact with the entities referred to in article 1. 5, in terms of the issues concerning the activities of the Council.

Article. 16. [the participation of professionals in the meetings of the Council] 1. To participate in the meetings of the Council, the President of the Council may invite specialists dealing with issues related to the prevention of drug addiction.

2. the Council shall deliver opinions and present the conclusions in the form of the resolutions taken by majority vote.

Article. 17. [team] in order to perform the tasks of the Council, the President of the Council may set up working parties, which include the members of the Council or other person, in particular the issues of counteracting drug addiction specialists.

Article. 18. [Return travel expenses of the members of the Council] 1. For participation in the work of the Council of the members of the Council shall not be entitled to remuneration.

2. the members of the Council shall be entitled to reimbursement of travel expenses on the principles set out in the regulations issued on the basis of art. 775 § 2 of the labour code.

Article. 18A. [risk assessment team risks to the health or life of humans related to the use of new psychoactive substances] 1. The competent Minister shall appoint the health risk assessment team risks to the health or life of humans related to the use of new psychoactive substances, hereinafter referred to as "the Team".

2. The team is an advisory body Advisory Committee the Minister responsible for health matters assessment of potential risks to the health or life of humans or the possibility of causing social harm arising out of the use of a substance for which there is a suspicion that the Act on the central nervous system.

3. the members of the team are specialists in matters referred to in paragraph 1. 2, with knowledge of at least the chemical sciences, pharmacology, toxicology, psychiatry, social sciences or sciences.

4. The band consists of: 1) members appointed by the Minister responsible for health, including the Chairman and Deputy Chairman;

2) members appointed by the Minister responsible for health at the request of: (a)) the Minister of Justice, (b)) the Minister of national defence, (c)) the Minister of Internal Affairs, (d)) the Minister responsible for the economy, e) the Minister responsible for transport.

5. the competent Minister health references team member: 1) on its own initiative, after consulting the authority, which has applied for the appointment of a member of the team, or 2) at the request of the authority, which has applied for the appointment of a member of the team, or 3) at his own request of a member of the team.

6. Administrative Support Team provides the main Sanitary Inspectorate.

7. the competent Minister in charge of health shall determine by way of interlocutory procedures, organisational chart of the team, taking into account its mandate and composition.

Article. 18B. [Task Team] 1. The team tasks: 1) the assessment of the potential risks to the health or life of humans or the possibility of causing social harm arising out of the use of a substance for which there is a suspicion that the Act on the central nervous system;

2) the assessment of the substance is not a new psychoactive substance, but showing the effects on the central nervous system, posing a direct threat to the health or life of humans or causing social damage, for putting her in the list of new psychoactive substances or in the list of narcotic drugs or psychotropic substances;

3) recommending the Minister competent for health changes in the annexes to the Act and the regulations issued on the basis of art. paragraph 44B. 2.2. The competent Minister shall make public health, through its public information Bulletin personal pages, ratings, and recommendations of the team, referred to in paragraph 1. 1 point 2 and 3.

Article. 18. [remuneration for participation in the work of the Team] 1. For participating in the work of a team shall not be entitled to remuneration.

2. The members of the team shall be entitled to reimbursement of travel expenses on the principles set out in the regulations issued on the basis of art. 775 § 2 of the labour code.

Article. 18 d [appointment of experts] the President of the Team on his own initiative or at the request of a member of the team may set up experts to submit reviews or to participate in the work of the team.



Chapter 3 Educational Activities, educational, informational and preventive Article. 19. [educational activities, educational, information and preventive] 1. Educational activities, educational, informational and preventive includes: 1) the promotion of mental health;

2) promotion of a healthy lifestyle;


3) to inform about the dangers of measures and substances whose use can lead to addiction, and drug abuse and its consequences;

4 psychological and social education);

5) legal education;

6) assistance.

2. the activities referred to in paragraph 1. 1, includes, in particular: 1) the issue of drug abuse prevention educational programs of the organizational units of the education system;

2) issues of drug abuse prevention programmes in the vocational education and prevention in schools and other education system and universities;

3) issue of drug abuse prevention to the programmes for the training of soldiers in the active military service;

4) preventive activities, in particular in environments at risk of addiction;

5) support for measures to national and local organizations, referred to in article 1. 5. 3, and other social initiatives;

6) mainstreaming drug abuse prevention in public broadcasting and other mass media;

7) conduct research on the issues of drug addiction.

3. Specific tasks from the scope of the educational activity, educational, information and preventive specifies the National Health Program.

Article. 20. [advertising] 1. You are prohibited from advertising and promotion psychotropic substances or drugs.

2. Medicinal products containing psychotropic or narcotic drugs can be advertised on the principles set out in the Act of 6 September 2001-pharmaceutical law.

3. it is prohibited to advertising and promotion of foodstuffs or other products by suggesting that: 1) they have an activity such as psychotropic or narcotic or 2) their use, even incompatible with the intended purpose, can cause effects such as effects of psychotropic substances or drugs.

Article. 21. [the task the Minister responsible for education and upbringing] 1. The competent Minister and education will take into account in the basis of the programme of general education issues of mental health promotion and healthy lifestyles, with particular emphasis on issues relating to the prevention of drug abuse.

2. the competent Minister and education in consultation with the competent Minister for health will take measures to take account of the issue of the promotion of mental health and a healthy lifestyle, including issues relating to the prevention of drug addiction in vocational teachers and people involved in the education and teaching of children and adolescents in schools and other educational system.

Article. 22. [obliged Authorities to carry out educational activity, educational, information and preventive] 1. The Ministers of the relevant educational and upbringing, health, internal affairs, public administration, transport, Minister of national defence and the Minister of Justice, each in respect of its operation, are required to develop and promote educational activities and preventive, undertaken in order to inform the public about the dangers of drug addiction.

2. the authorities referred to in paragraph 1. 1 are obliged to operate educational, educational, preventive and information to: 1) the promotion of a healthy lifestyle;

2) supporting the activities of national and local organizations, referred to in article 1. 5. 3, and other social initiatives.

3. the competent Minister and education, in consultation with the competent Minister for health, shall determine, by regulation, scope and forms of conduct in schools and education system institutions educational activity, educational, information and preventive, having regard to the welfare of children and young people.

Article. 23. [scientific Unit] 1. The Ministers of the right to health, higher education, public finance, Home Affairs, transport, labour, science, Minister of Justice and Minister of national defence establish arrangements to carry out scientific research on the issues of drug abuse and epidemiological studies.

2. scientific Units performing tasks in the field of scientific research on the issues of drug addiction, if it is necessary for the conduct of such studies, may possess, store, and purchase of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, after obtaining appropriate authorization referred to in article 2. 35 paragraph 1. 1 point 2 and 3 and paragraphs 1 and 2. 2.3. Scientific units referred to in paragraph 1. 2, may hold, store and purchase substitutes or new psychoactive substances after the notification, referred to in article 2. 241 of paragraph 1. 1 point 2.

Article. 24. [the realization of tasks related to the prevention of drug addiction] 1. The Ministers of the right to health, and education, internal affairs, public administration, public finances, transport, labour and the Minister of national defence and the Minister of Justice shall ensure the preparation of the necessary number of people to carry out the tasks referred to in article 1. 2. 1.2. Agencies of government administration, organizational units, the prison service, military police, and universities leading training of persons referred to in paragraph 1. 1, can hold, store and purchase narcotic drugs, psychotropic substances, their preparations, category 1 precursors, substitution or new psychoactive substances in quantities necessary to conduct this training.

3. (repealed) 4. The entities referred to in paragraph 1. 2, and scientific units have, store and purchase measures, substances and preparations referred to in paragraph 1. 2, if they carry out their research in order to identify and confirm the offence or infringement of the prohibition referred to in article 1. paragraph 44B. 1 point 1 or 2.

5. (repealed) 6. (repealed)

Article. 241. [notification of research to their respective owners] 1. Research, referred to in article 1. 23 paragraph 1. 2 and art. 24 paragraph. 4, be notified before their start, in paper or electronic form, to: 1) provincial pharmaceutical Inspector, in the case of narcotic drugs, psychotropic substances, their preparations, the precursors of category 1 or 2) the State of health of the state sanitary inspector or provincial inspector of the Ministry of internal affairs – in the case of replacement or new psychoactive substances – the correct due to the established scientific unit or entity carrying out the test.

2. scientific Units and entities referred to in article 1. 23 paragraph 1. 2 and art. 24 paragraph. 2 and 4, are obliged to: 1) the acquisition of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances from traders with the authorization referred to in article 2. 35 paragraph 1. 1, art. 36 paragraph 1. 1 or article. 40(2). 1 and 2, paragraph 1, or to raise them from the organizational units of the public finance sector, scientific units or entities initiating research in order to identify and confirm the offence or infringement of the prohibition referred to in article 1. paragraph 44B. 1 paragraph 1 or 2, in an amount necessary to carry out the research or training;

2) check-in of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances in an orderly manner, according to the date of their acquisition or entry into their possession, for a period of 5 years from the end of the calendar year, the last entry in the records;

3) storage or possession of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances in a manner against theft or destruction and against access by unauthorized persons to them;

4) destruction of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances in a way that prevents unauthorized access to them.

3. the competent Minister of health in consultation with the Ministers competent for internal affairs, public finance, higher education, science, the Minister of national defence and the Minister of Justice shall determine by regulation: 1) the manner and mode of acquisition or coming into possession, accounting, storage and use of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances in order to carry out research or training referred to in article 1. 23 paragraph 1. 2 and art. 24 paragraph. 2 and 4, whereas the security of their storage and the need to develop a separate records for a given measure, of the substance or preparation;

2) the manner and mode of transmission of applications referred to in paragraph 1. 1 scope of the information and designs applications, taking into account the need to ensure efficiency in the transmission of notifications and to ensure clarity and consistency of information;

3) destruction of narcotic drugs, psychotropic substances, their preparations, category 1 precursors, measures or new psychoactive substances, taking into account the need to safeguard these measures, the substances or preparations before access to unauthorised persons and to ensure the safety of persons involved in their destruction.


Article. 24A. [the entity entitled to the possession of narcotic drugs] 1. Agencies of the Government and the military police carrying out emergency operations, reconnaissance, and agencies of the customs service in the performance of the tasks referred to by the law of 27 August 2009 of the Customs Service (Journal of laws of 2015.990, as amended) may come into possession of narcotic drugs, psychotropic substances or their preparations and category 1 precursors in quantities necessary for research evidence of a crime.

2. the Entities referred to in paragraph 1. 1, in connection with the performance of the activities and actions referred to in this provision are required to: 1) store your narcotics, psychotropic substances or their preparations and category 1 precursors in a manner against theft and destruction;

2) to destroy the narcotic drugs, psychotropic substances or their preparations and category 1 precursors to prevent access of unauthorised persons.

3. the Council of Ministers shall determine, by regulation, entities entitled to destruction of narcotic drugs, psychotropic substances or their preparations and category 1 precursors, obtained through the activities and actions referred to in paragraph 1. 1, as well as detailed the procedure and conditions for their storage and destruction, with a view to the need to safeguard these measures and substances from third party access.

Article. 24B. [transfer of information about the people seeking treatment] 1. Medicinal entities leading treatment or rehabilitation of addicts are obliged to cooperate with the Office, in particular, to collect and Transfer Agent info on people seeking treatment due to the use of narcotic drugs, psychotropic substances or substitutes.

2. The information referred to in paragraph 1. 1, includes: 1) ID that prevents the identification of the person referred to in paragraph 1. 1, consisting of the first 2 letters of the name, first 2 letters of the name, date of birth, and coded information about the gender of the patient;

2) the characteristics of the socio-demographic of the person referred to in paragraph 1. 1, containing data on the place of residence, education and citizenship;

3) use the substances referred to in paragraph 1. 1, which contains the type and status of the use of narcotic drugs, psychotropic substances or substitutes, the frequency of their use and how they adopt;

4) history of the use of narcotic drugs, psychotropic substances or substitutes, including age of initiation, use individual substances and age begin using problem;

5) the behaviour of the risky that could contribute to HIV, HCV and HIV, HCV serostatus;

6) history of treatment, including information about the continuation and end of treatment;

7) medical diagnosis according to the current international classification of diseases and related health problems ICD;

8) other information required by the European Monitoring Centre for drugs and drug addiction non-personal information referred to in article 1. 27 paragraph. 1 of the law of 29 August 1997 on the protection of personal data (Journal of laws of 2015, item 2135 and 2281).

3. the competent Minister in charge of health shall determine, by regulation, scope and mode of cooperation with the Office of medical entities engaged in treatment or rehabilitation of that use of narcotic drugs, psychotropic substances or substitutes, how we collect, store and process the information referred to in paragraph 1. 1, the mode of transmission and the pattern of individual reporting questionnaire to the reporter for treatment due to the use of narcotic drugs, psychotropic substances or substitutes, taking into account the need to protect the privacy of people, referred to in paragraph 1. 1. Chapter 4 dealing with addicted persons Article. 25. [Voluntary treatment, rehabilitation or reintegration of addicts] treatment, rehabilitation or reintegration of addicts is voluntary, if the provisions of the Act does not provide otherwise.

Article. 26. [Treatment, rehabilitation, reintegration] 1. Treatment of persons linked to the leads entity curative or a doctor practising under the professional practice.

2. The rehabilitation of people addicted can lead: 1) the physician having specialization in the field of Psychiatry;

2) person with specialist drug therapy certificate.

3. In the rehabilitation of people addicted can participate a person certified instructor of addiction therapy.

4. Reintegration of addicts can lead social integration centres, created on the basis of the provisions of the employment, and the entities referred to in paragraph 1. 1 and 2 and in articles. 5. 3. the 5. Benefits referred to in paragraph 1. 1 – 4, provided the person relying party regardless of the place of residence in the country is from the people charges.

Article. 27. [Certificates specialist drug therapy and drug therapy instructor] 1. The certificates referred to in article 1. 26 paragraph. 2 and 3, are issued to persons who have completed training in the field of addiction, in accordance with the preferred choice by way of a competition carried out by the Office at least once in a calendar year.

2. Offer contests, submitted to the offices, contain the following data: 1) the name and surname and place of residence and address or name (company), registered office and address of the tenderer;

2) organizational and legal form of the tenderer;

3) [1] number of the entry of the tenderer to register in the national court register or another competent registry and tax identification number (Tin) if the successful tenderer such numbers holds;

4) place of training;

5) planned start and end dates;

6) training program.

3. Operator training is required to ensure: 1) the staff of the teaching of skills appropriate for the proper conduct of training;

2) appropriate for the implementation of the training base of teaching;

3) having an internal evaluation of the quality of education, to take account of quality assessment tools and methods in this evaluation.

4. tenders shall consider the jury chosen by the head of the Office.

5. The training referred to in paragraph 1. 1, ends the exam organized by the Office at least twice a year.

6. Final examination consists of written and oral parts.

7. Certified Addiction specialist can get a person who graduated from higher education.

8. drug therapy instructor Certificate holder may receive education at least medium.

8A. Applicants for certificates referred to in article 1. 26 paragraph. 2 paragraph 2 and paragraph 3. 3, are obliged, under pain of having to undergo training, take the exam within no more than 4 years since the start of the training.

9. persons who have successfully completed training referred to in paragraph 1. 1, and certified instructor of addiction therapy and within 3 years from the completion of this training met the requirements referred to in paragraph 1. 7, can take the test in the field of addiction therapy specialist without having to participate in the training, but not later than the year after obtaining the master's degree.

10. Training costs referred to in paragraph 1. 1, the test and the issuance of the certificate shall be borne by the participant of the training.

11. the Office shall keep a register of the issued certificates.

12. the competent Minister in charge of health shall determine, by regulation, for the submission of tenders, the criteria for their evaluation and dates of competition proceedings referred to in paragraph 1. 1, taking into account the need to ensure the highest level of training.

13. the competent Minister in charge of health shall determine by regulation: 1) requirements to be met by operators of training in the field of addictions, 2) framework for training programmes in the field of addictions, 3) mode and manner of the examination, 4) the composition of the Board conducting the exam, 5) specimens of the certificates: instructor of addiction and addiction therapy specialist – having regard to the need to ensure the highest level of training and its type.

Article. 27. [request for training in the field of addictions] 1. The head of the Office can finance the cost of training in the field of addiction of its participants, at their request, made through the operator training in the field of addictions, if they are employed in the units conducting rehabilitation, including, in particular, those listed in article 2. 86.2. The head of the Office indicates the deadline for submission of applications referred to in paragraph 1. 1, and also sets the maximum amount of yearly funding per one participant training in the field of addiction and the number of persons covered by the grant, in view of the amount of appropriations provided for this purpose in the financial plan of the Office.

3. the data referred to in paragraph 1. 2, Director of the Office shall, as soon as they determine, on the public information Bulletin of the Office.

4. the request referred to in paragraph 1. 1, includes: 1) first and last name;

2) the address of the place of residence;

3) the start and end of the training in the field of addiction;

4) the reason for the request.

5. funding the costs of training in the field of addiction decides, subject to the provisions of paragraph 2. 1, the order of the impact of the proposals referred to in paragraph 1. 1, out of funds provided for this purpose in the financial plan of the Office.

Article. 28. [replacement therapy] 1. Depends on the person can be treated by applying substitution treatment.


2. Replacement therapy can lead the medicinal entity after authorization by the Marshal of the proper due to the resident of this entity, issued after obtaining the favourable opinion of the head of the Office with regard to complying with the requirements set out in the regulations issued on the basis of paragraph 1. 7.3. Residence permit for replacement therapy in subjects for persons deprived of their freedom, it seems the Director-General of the prison service after obtaining the favourable opinion of the head of the Office.

4. the authorization for substitution treatment may receive medicinal entity that has: 1) a pharmacy, hospital or has entered into an agreement with a pharmacy or a pharmaceutical warehouse in terms of supply of substitute measure;

2) room designed to: (a)) the issue of substitute measure, b) conduct group therapy, c) doctor, therapist and social worker, d) sampling for analysis, e) storage and preparation of substitute measures to prevent the access of unauthorised persons;

3) staffing conditions to ensure the implementation of the programme conduct outpatient treatment concerning, in particular, the head of the program, and trained in the field of program nurses and support staff.

5. the authorisation referred to in paragraph 1. 2 and 3, shall be issued by administrative decision.

6. the authorization for substitution treatment be withdrawn when the medicinal entity no longer meets the conditions which form the basis of an authorisation.

6a. In order to exclude the participation of the patient at the same time in more than one program substitution treatment Office leads the central list of persons subject to Substitution Treatment.

6B. the leading therapeutic substitution treatment is obliged to immediately communicate to the Office information about qualified, disabled or end participation of the patient in pursuing such treatment.

7. the competent Minister in charge of health shall determine, by regulation, a detailed procedure in the treatment of substitution, specific conditions, which should satisfy the entity carrying out the medicinal replacement therapy, and detailed collection, storage and transmission of the information referred to in paragraph 1. 6B, bearing in mind the welfare of addicts, including the need to preserve the anonymity of the data are placed in the central list of persons covered by Substitution Treatment.

Article. 29. [addicts in correctional facilities and shelters for minors] 1. In correctional facilities and shelters for minors and organizational units the prison service leads to treatment, rehabilitation and reintegration of addicts are placed in these establishments.

2. The Minister of Justice in consultation with the competent Minister for health shall determine, by regulation, the detailed conditions and the treatment, rehabilitation and reintegracyjnego in relation to the addicts, located in: 1) correctional facilities and shelters for minors, 2) organizational units the prison service – with a view to the welfare of the people in these units.

Article. 30. [Compulsory treatment and rehabilitation] 1. At the request of the legal representative, the relatives in the direct line, siblings or the actual guardian or from the Office of family court may refer the minor person based on compulsory treatment and rehabilitation.

2. The time of compulsory treatment and rehabilitation is not determined in advance, he may not, however, be longer than 2 years.

3. If the person subject to complete 18 years before the end of the compulsory treatment or rehabilitation, the family court may be extended for the time necessary to achieve the purpose of treatment or rehabilitation, including not more than referred to in paragraph 1. 2.4. Proceedings in the cases referred to in paragraph 1. 1, takes place according to the rules of the proceedings in cases of minors.



Chapter 5 of the Precursors, narcotic drugs, psychotropic substances, substitution and new psychoactive substances Article. 31. [the Division of narcotic drugs] 1. Drugs are divided into groups according to the degree of risk of addiction when used for purposes other than medical and the scope of their use for medical purposes.

2. the Division of narcotic drugs for the Group and-N, N, N-and IV-N specifies the annex No. 1 to the Act.

Article. 32. [the Division of psychotropic substances] 1. Psychotropic substances are divided into groups according to the degree of risk of addiction when used for purposes other than medical and the scope of their use for medical purposes.

2. Division of psychotropic substances in the Group I-P, P, P-III and IV-P specifies the Appendix No 2 to the Act.

Article. 33. [narcotic, psychotropic substances used for medical purposes] 1. Drugs groups and-N and II-N and psychotropic substances groups II-P, P-III and IV-P may only be used for medical, industrial or research.

2. Psychotropic substances group and-P may be used only for research purposes, and the narcotic Group IV-N for the sole purpose of research and in the medicinal uses of animals-to the extent indicated in annex 1 to this Act.

Article. 34. [shall be entitled to the possession of narcotic drugs, psychotropic substances] 1. Narcotic drugs, psychotropic substances or their preparations and category 1 precursors may have only the entrepreneur, organizational unit or person entitled under the provisions of the Act, regulation 273/2004 or regulation 111/2005.

2. Held without permission narcotic, psychotropic substances or their preparations and category 1 precursors are subject to protection by law enforcement authorities, or the Customs authorities in accordance with the provisions of the criminal proceedings.

3. Where no criminal proceedings have been instituted, for forfeiture to the Exchequer of narcotic drugs, psychotropic substances or their precursors preparations and category 1 Court at the request of provincial pharmaceutical inspector or Chief pharmaceutical Inspector Troops Polish.

4. In case the award by the Court for forfeiture to the Exchequer of narcotic drugs, psychotropic substances or their preparations and category 1 precursors, they are subject to destruction. The Court may order, at the request of individuals, as referred to in article. 24 paragraph. 2 and 4, the forfeiture to the Exchequer of narcotic drugs, psychotropic substances or their preparations and category 1 precursors by passing them in all or part of the units.

5. (repealed) Article. 35. [the production, processing or altering of narcotic drugs or psychotropic substances] 1. Permit the main pharmaceutical Inspector requires to take the business of: 1) manufacturing, processing, processing, importation or distribution of narcotic drugs or psychotropic substances;

2) manufacture, processing, processing, import, distribution or use of the purpose of scientific research, in the field of their statutory activities, category 1 precursors;

3) manufacturing, processing, processing for the purposes of scientific research, scientific units within its statutory activity, of narcotic drugs groups and-N,-N II and IV-N or psychotropic substances and groups-P, P, P-III and IV-P.

2. the application for the purposes of scientific research, scientific units within its statutory activity, of narcotic drugs or psychotropic substances requires the authorisation of the provincial pharmaceutical Inspector.

3. Does not require the authorisation of processing of narcotic drugs, psychotropic substances and precursors, if it is made in a pharmacy on the principles set out in the Act of 6 September 2001-pharmaceutical law.

4. the authorisation referred to in paragraph 1. 1 and 2, it seems: 1) after it has been established by the main Pharmaceutical Inspectorate production Affairs, that the trader licensed, referred to in article 2. 38 paragraph 2. 1 of the Act of 6 September 2001-pharmaceutical law, or entered in the register referred to in article 1. 51B paragraph. 1 of this Act, fulfils the conditions laid down the provisions of the Act, (a) in the case of category 1 precursors also conditions laid down by the provisions of regulation 273/2004, Regulation 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005 laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and for Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade in drug precursors between the community and third countries (OJ. EU L 202 of 03.08.2005, p. 7);

2) when satisfied by the provincial pharmaceutical Inspector that the trader, other than referred to in point 1, who plays for a permit satisfies the conditions referred to the provisions of the Act, (a) in the case of category 1 precursors also conditions laid down by the provisions of regulation 273/2004, Regulation 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005 laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and for Council Regulation (EC) No 111/2005 laying down rules for the monitoring trade in drug precursors between the community and third countries.

5. the authorisation referred to in paragraph 1. 1 and 2, define the allowed amount and the purpose of the manufacture, processing, processing, import, distribution or use of narcotic, psychotropic substance or category 1 precursors.

6. The trader referred to in paragraph 1. 4, shall be required to: 1) keep records concerning narcotic, psychotropic substances or precursors of category 1;


2) store your narcotics, psychotropic substances or category 1 precursors in a manner against theft or destruction, including during their transportation.

7. the competent Minister in charge of health shall determine by regulation: 1) specific conditions and for issuing and withdrawing authorisations referred to in paragraph 1. 1 and 2, including eligibility requirements, which should correspond to the person responsible for the supervision of the manufacture, processing, conversion, import, distribution, marketing or use of the purpose of scientific research of narcotic drugs, psychotropic substances or precursors of category 1, with a view to ensuring the correct safeguards against the use of narcotic drugs or psychotropic substances authorised by unauthorised persons or for purposes other than those specified in the authorisation;

2) patterns of applications for authorisation of the manufacturing, processing, processing, importation, distribution, marketing or use of the purpose of scientific research of narcotic drugs, psychotropic substances or precursors of category 1, taking into account the efficiency and transparency of the proceedings;

3) the conditions and the way the issue of narcotic drugs, psychotropic substances or precursors of category 1 and check-in manufacturing, processing, processing, import, distribution, marketing or use of the purpose of scientific research of narcotic drugs, psychotropic substances or precursors of category 1, with a view to the safety of storage and the need to develop a separate records for a given measure, substance or precursor.

Article. 36. [collection of lotions and opium poppy with makowego and herb or resin of cannabis other than fibrous] 1. A collection of makowego milk and opium from poppy and cannabis resin or herb other than fibrous is permitted solely for the purpose of carrying out scientific research, after authorization by the Main pharmaceutical Inspector.

2. Preparation of extracts from poppy straw may only take place on entrepreneurs and scientific unit and Central Test Centre Cultivars – within the scope of their statutory activity, after authorization by the Main pharmaceutical Inspector.

3. the competent Minister in charge of health shall determine, by regulation, conditions and procedure for issuing and withdrawing authorisations referred to in paragraph 1. 1 and 2, and the content of the application for the issue of those permits, having regard to the principle of respect for the rights of the party seeking authorisation and to ensure the efficiency of the proceedings.

Article. 37. [entities entitled to narcotic or psychotropic substances] 1. The import, export, intra-Community supply or intra-Community acquisition of narcotic drugs or psychotropic substances can be made by entrepreneurs with the authorisation referred to in article 1. 35 paragraph 1. 1 paragraph 1 or article. 40(2). 1, with the permission of the main pharmaceutical Inspector specifying products or substances, which may be the subject of imports, exports, intra-Community delivery or intra-Community acquisition.

2. Import or intra-Community acquisition of narcotic drugs or psychotropic substances may be made by individuals, referred to in article 1. 35 paragraph 1. 1 paragraph 3 and paragraph 4. 2, with the permission of the main pharmaceutical Inspector specifying products or substances, which may be the subject of the importation or intra-Community acquisition.

3. Import or intra-Community acquisition of narcotic drugs or psychotropic substances may occur once, for each consignment imported to the territory of the Republic of Poland: 1) import licences or intra-Community acquisition, issued by the main pharmaceutical Inspector, and 2) export licence or on intra-Community supply, issued by the competent authorities of the country of export.

4. Export or intra-Community supply of narcotic drugs or psychotropic substances may occur once, for each consignment exported from the territory of the Republic of Poland, the export licence or on intra-Community supply, issued by the main pharmaceutical Inspector on the basis of a licence to import or intra-Community acquisition, issued by the competent authority of the importing country.

5. imports, exports, intra-Community supply or intra-Community acquisition of poppy straw may be made only by the operators referred to in article 1. 35 paragraph 1. 1 paragraph 1 or article. 40(2). 1, after obtaining the licences provided for in paragraph 1. 3 and 4.

6. The passage through the territory of the Republic of Poland of narcotic drugs, psychotropic substances and poppy straw is allowed on the basis of the export licences issued by the competent authorities of the country of export for each consignment.

7. In the cases referred to in paragraph 1. 3-6, the export licence or the intra-Community supply are appended to each consignment.

8. the importation of narcotic drugs to the customs warehouse is prohibited.

9. the importation of narcotic drugs, psychotropic substances into free zones is prohibited.

10. Import, export, intra-Community supply or intra-Community acquisition of narcotic drugs, psychotropic substances or precursors of category 1 for their own treatment can be carried out on the basis of the documents referred to in regulations issued on the basis of paragraph 1. 12.11. Licences for the import, export, intra-Community delivery or intra-Community acquisition of narcotic drugs and psychotropic substances which are stocks of the organizational units of the Ministry of defence is involved in missions, exercises or training outside the country grants the Chief Pharmaceutical Inspector Polish Troops at the request of the leader (Commander, Commander, the head of) an organizational unit.

12. the competent Minister in charge of health shall determine, by regulation, the detailed conditions and the issue of licences and the documents referred to in paragraph 1. 3, 4 and 10, patterns of these licences and documents, obligations of operators and the holders of these permits and documents in the depository of the measures covered by the licence, the issuance of these measures, units eligible and documentation in their possession and marketing of them, with a view to the efficiency of the proceedings on the grant of licences.

Article. 38. [Main Pharmaceutical Inspector] 1. Traders established in the manufacture, processing, processing, import, export, intra-Community delivery or intra-Community acquisition and marketing wholesale category 1 precursors and 4 communicate the main Pharmaceutical Inspector about any of suspicion as to the compliance with the provisions of the law: 1) orders to these substances;

2) activities involving these substances;

3) attempts to use these substances.

2. the provisions of paragraphs 1 and 2. 1 shall also apply to the precursors of categories 2 and 3, except that the information referred to in those provisions, shall be the principal Officer Killed.

3. Main Pharmaceutical Inspector with regard to precursors in categories 1 and 4, and the main Sanitary Inspector in respect of precursors of categories 2 and 3, in justified cases, inform the police, border guard and Customs authorities about the need to stop the shipment of precursors, which does not meet the requirements laid down in law.

4. Chief Inspector pharmaceutical and Chief Inspector Plumbing keep records of information obtained in paragraph 2. 1 and 2.

5. the competent Minister of health, in consultation with the competent Minister of public financies and the competent Minister of the Interior, shall determine by regulation: 1) the detailed how to pass information, 2) way to keep records of information obtained in paragraph 2. 1 and 2, 3) the detailed mode and method of notification referred to in paragraph 1. 3, and the pattern of such notification, 4) mode and the treatment of the consignment referred to in paragraph 1. 3 – whereas to prevent illicit manufacture precursors.

Article. 39. [marketing authorisation for narcotic drugs, psychotropic substances] 1. The authorisation referred to in article 1. 35 paragraph 1. 1 and 2, article. 36 paragraph 1. 1 and 2, article. 40(2). 1 and 2 and article. 49 paragraphs 1 and 2. 1, and licences referred to in article 1. 37 paragraph 2. 1-6 shall be granted at the request of the principal applicant, a specified period of time or for an indefinite period.

2. before taking a decision on the permit or the licence issuing authority of the permit or the licence, hereinafter referred to as "the body issue", you may: 1) call upon the entity applying to be completed, within the prescribed period, the missing documentation attesting that it meets the conditions set out the provisions of the Act;

2) control check the facts stated in the application for a permit or licence, in order to determine whether the applicant meets the conditions for the exercise of the activities covered by the authorization or permission.

3. The granting of authorisation or licence, modification of an authorisation or licence, refusal to grant a permit or licence and the withdrawal of authorisation or licence is by way of a decision. The decision to withdraw an authorization or a permit is subject to immediate execution.

4. the authorising Authority if the information about that entity that is granted a residence permit or authorization, work in a manner inconsistent with the provisions of the Act governing the activities covered by the authorization or licence, shall designate a term immediately to remove those irregularities.

5. the authorising Authority shall withdraw an authorisation or licence, if: 1) the entity that is granted a residence permit or authorisation, no longer fulfils the conditions required for the performance of the activities referred to in the permit or licence;


2) an entity referred to in paragraph 1, not removed, within the prescribed time limit, the authorising authority, factual and legal background in accordance with the provisions of the Act governing the activities covered by the authorization or permission.

6. the approved permit or authorization, is obliged to report to the authority to travel to any changes to the data specified in the permit or licence.

7. The entity to whom a permit has been withdrawn for the reasons referred to in paragraph 1. 5, can apply for a residence permit to the same extent not earlier than after 3 years from the date of adoption of the decision to withdraw authorization.

8. By submission of an application for authorisation of the manufacturing, processing, processing, distribution, wholesale, cultivation, collection or use for testing and licences for the import, export, intra-Community acquisition and the intra-Community supply of narcotic drugs, psychotropic substances and precursors in categories 1 and 4, as well as the change of those permits or licences are fees, which represent a revenue of the State budget.

9. The fee referred to in paragraph 1. 8, the current account authority authorising: 1) 750 zł-for filing an application for a permit to wholesale, distribution, manufacture, processing, processing or application to the research of narcotic drugs, psychotropic substances or precursors of category 1;

2) 750 zł-for filing an application for a permit on a collection of lotions and opium poppy with makowego and herb or resin of cannabis other than fibrous;

3) 750 zł-for filing an application for a permit for the cultivation of opium poppy and cannabis conducted by the scientific and Research Centre Cultivars;

4) 350 zł-for filing an application for amendment of the authorisation referred to in paragraph 1-3;

5) 100 zł-for filing an application for an import licence, export, intra-Community acquisition or intra-Community supply of narcotic drugs or psychotropic substances;

6) 100 zł-for filing an application for a permit to export precursors of category 4;

7) 100 zł-for filing an application for the issue of import or export licences of category 1 precursors;

8) 50 zł-for filing an application to amend a permit or licence referred to in paragraph 5-7.

10. the application referred to in paragraph 1. 8, shall be accompanied by proof of lodging of charges. In the absence of proof of payment of the fee, the application is left unexamined.

Article. 40. [wholesale narcotic drugs or psychotropic substances] 1. Permit the main pharmaceutical Inspector requires wholesale narcotic drugs or psychotropic substances.

2. Main Pharmaceutical Inspector at the request of the operator, it seems: 1) permission to wholesale category 1 precursors, in accordance with the provisions of regulation 273/2004, Regulation 111/2005 and Commission Regulation (EC) No 1277/2005 of 27 July 2005 laying down implementing rules for Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and for Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade in drug precursors between the community and third countries;

2) a permit to export precursors of category 4, in accordance with the provisions of Regulation 111/2005;

3) simplified export authorisation precursors of category 4, in accordance with the provisions of the European Union governing rules for the monitoring of trade in drug precursors between the community and third countries, if this does not cause the risk of illicit use of precursors of category 4.

3. The trader referred to in paragraph 1. 2, shall be required to: 1) keep records concerning narcotic, psychotropic substances or precursors of category 1;

2) store your narcotics, psychotropic substances or category 1 precursors in a manner against theft or destruction, including during their transportation.

4. the authorisation referred to in paragraph 1. 1 and paragraph 2. 2, paragraph 1, seems to be having: 1) by the Inspector for the main Pharmaceutical Inspectorate wholesale trader licensed, referred to in article 1. paragraph 76. 1 of the Act of 6 September 2001-pharmaceutical law, meets the conditions laid down the provisions of the Act;

2) by provincial pharmaceutical Inspector that the trader, other than referred to in point 1, who plays for a permit satisfies the conditions referred to the provisions of the Act.

5. the competent Minister in charge of health shall determine by regulation: 1) specific conditions and for issuing and withdrawing authorisations referred to in paragraph 1. 1, including eligibility requirements, which should correspond to the person responsible for supervising the turnover of narcotic drugs, psychotropic substances or precursors of category 1, with a view to ensuring the correct safeguards against the use of narcotic drugs, psychotropic substances or precursors of category 1, authorised by unauthorised persons or for purposes other than those specified in the authorisation;

2) patterns of applications for marketing authorisation for a narcotic, psychotropową substance or category 1 precursors, taking account of the efficiency and transparency of the proceedings;

3) the conditions and the way the issue of narcotic drugs, psychotropic substances or precursors of category 1 and check-in narcotic drugs, psychotropic substances or precursors to category 1, bearing in mind the safety of storage and the need to develop a separate records for a given measure, substance or precursor.

Article. 41. [the retail turnover of narcotic drugs, psychotropic substances] 1. The retail turnover of narcotic drugs, psychotropic substances and precursors which are medicinal products are leading pharmacies and pharmacy points, providing the appropriate conditions for their storage to prevent the access of unauthorised persons to these measures and substances.

2. Preparations containing narcotic or psychotropic substances shall be issued from the pharmacy solely on the basis of specially marked prescription or demand, subject to paragraph 2. 4.3. The entities referred to in paragraph 1. 1, article 12 shall apply. 40(2). 3.4. Preparations containing narcotic Group II-N or psychotropic substances groups III-P and IV-P can be issued from the pharmacy on prescription other than those referred to in paragraph 1. 2, and preparations containing narcotic Group III-N can be issued from a pharmacy without a prescription.

5. the competent Minister in charge of health shall determine by regulation: 1) specific conditions for storage by the pharmacy of narcotic drugs, psychotropic substances, precursors of category 1 and preparations containing these products or substances and the manner in which the documentation in their possession and, having regard to the protection of these substances from third party access;

2) the specific terms and conditions issuance of prescriptions and requests for preparations containing narcotic drugs or psychotropic substances, the designs of these documents and the issue of these preparations from an online pharmacy, taking into account the security conditions of distribution.

Article. 42. [Entities having medicinal products containing narcotic or psychotropic substances] 1. The entity, which, in accordance with the provisions of the Act of 6 September 2001-pharmaceutical law – did not create a hospital pharmacy or Department of hospital pharmacy, medicinal plant and the doctor, dentist, or veterinarian, practising under the professional practice, as well as other entity whose business requires you to have and use of medical preparations containing narcotic drugs groups and-N, N, N-and IV-N or psychotropic substances groups II-P , III-P and IV-P, possess and apply these preparations, if they are authorised as a medicinal products pursuant to the provisions of the pharmaceutical law, and after obtaining the consent of the provincial pharmaceutical Inspector.

2. Entity, which, in accordance with the provisions of the Act of 6 September 2001-pharmaceutical law – did not create a hospital pharmacy, medicinal plant and the doctor, dentist, or veterinarian, practising under the professional practice, which for the purposes of carrying out clinical trials requires the possession and the use of preparations containing narcotic drugs groups and-N, N, N-and IV-N or psychotropic substances groups II-P , III-P and IV-P, possess and apply those preparations after obtaining the consent of the provincial pharmaceutical Inspector.

3. Provincial pharmaceutical inspector shall: 1) referred to in paragraph 1. 1-for a specified period, not exceeding 3 years;

2) referred to in paragraph 1. 2-for a limited period, not longer than specified in the authorization to conduct a clinical trial.

4. the competent Minister in charge of health shall determine by regulation: 1) the application for authorisation referred to in paragraph 1. 1 and 2, taking into account the need to ensure the efficiency of the proceedings;

2) types of preparations containing narcotic drugs and psychotropic substances, which may be held for medical purposes, or applied to clinical trials, together with an indication of their number and the group to which they are qualified, having regard to the need for proper identification;

3) conditions of supply and storage of preparations containing narcotic drugs and psychotropic substances for medical purposes held or used for clinical trials, having regard to the need to safeguard these substances against misuse;

4) types of entities whose activities require the possession and use of preparations containing narcotic drugs and psychotropic substances, and the way you do by the documentation, bearing in mind the safety of storage and the need to develop a separate documentation for a given product or substance.


Article. 43. [report of the activities specified in the permit or licence] 1. The entrepreneur and the other organizational unit, who have obtained the authorisation referred to in article 1. 35 paragraph 1. 1 and 2, or article. 40(2). 1 and 2, or the authorisation referred to in article 1. 37 paragraph 2. 3-5, shall be required to submit the main Pharmaceutical Inspector activity reports specified in the permit or licence.

2. the competent Minister in charge of health shall determine, by regulation, the detailed terms and conditions, and the deadlines for submission of the reports referred to in paragraph 1. 1, having regard to the necessary data, which should contain.

Article. 44. [for supervision of the handling of narcotic drugs, psychotropic substances] 1. Supervision of the crops referred to in article 1. 49 paragraphs 1 and 2. 1, manufacture, processing, conversion, import, distribution, marketing and destruction or use in order to carry out scientific research of narcotic drugs, psychotropic substances and precursors of category 1 holds the provincial pharmaceutical Inspector competent for the registered office of the trader or the scientific unit – through the implementation of the obligations arising under regulation 273/2004, Regulation 111/2005 and the provisions of the Act, with the exception of the traders referred to in paragraph 1. 2A. 2. Supervision of the precursors to categories 2 and 3 shall exercise the State Sanitary Inspector district court competent for the registered office of the manufacturer, importer or other person applying on the market – by controlling the execution of the obligations imposed on the manufacturer, the importer or other party placing on the market under the Act, regulation 273/2004 and Regulation 111/2005 and the issue of licences – on the principles and specific provisions on State health inspection , regulation 273/2004 and Regulation 111/2005.

2A. the Chief Inspector Pharmaceutical supervises: 1) manufacture, processing, conversion, import, distribution and destruction of narcotic drugs, psychotropic substances and precursors of category 1 by the trader authorised, as referred to in article. 38 paragraph 2. 1 of the Act of 6 September 2001-pharmaceutical law, or the trader entered in the register referred to in article 2. 51B paragraph. 1 this Act is implemented under the control of the fulfilment of the obligations arising from the provisions of regulation 273/2004 and Regulation 111/2005 and the provisions of the Act;

2) wholesale turnover of narcotic drugs, psychotropic substances or precursors to category 1 by the trader authorised, as referred to in article. paragraph 76. 1 of the Act of 6 September 2001-pharmaceutical law is implemented under the control of the fulfilment of the obligations arising from the provisions of regulation 273/2004 and Regulation 111/2005 and the provisions of the Act;

3) the export of precursors of category 4 by the trader authorised, as referred to in article. 38 paragraph 2. 1 or article. paragraph 76. 1 of the Act of 6 September 2001-pharmaceutical law is implemented under the control of the fulfilment of the obligations arising from the provisions of Regulation 111/2005 and the provisions of the Act.

3. The competent authority of the notification of export to third countries in the field of precursors of categories 2 and 3, referred to in article 2. 11 (1). 1 and 2 Regulation 111/2005, is the main Sanitary Inspector.

4. Tasks of the scope of registration referred to in article 1. 3 paragraphs 1 and 2. 6 regulation 273/2004, including keeping a national register of operators and users who have been granted registration, executes the Inspector for chemical substances. The grant, refusal, suspension or cancellation of registration takes place by means of a decision. Inspector for chemical substances, notify the appropriate State district health inspector about the decision.

5. the competent Minister in charge of health shall communicate to the Commission the European information referred to in article 1. 13 and 16 of regulation 273/2004 and article. 32 Regulation 111/2005.

6. the Minister of Defence supervises the processing, storage, trading and stocks of narcotic drugs and psychotropic substances in the subordinate organizational units – on the principles and specified in the provisions referred to in paragraph 1. 1 and 2.

7. the competent Minister for Internal Affairs supervises the processing, storage, marketing and inventory of precursors of the group categories 2 and 3 in the subordinate organizational units – on the principles and specified in the provisions referred to in paragraph 1. 2.8. Those who in the course of his business are broken, counterfeit drugs, psychotropic substances or precursors of category 1 mixtures, as well as medicinal products or components which expired, destroy these substances as specified in the regulation referred to in paragraph 1. 9.9. The competent Minister in charge of health shall determine, by regulation, the detailed terms and procedures of narcotic drugs, psychotropic substances and precursors to category 1, their mixtures or waste, medicinal products, corrupt, falsified or expired, containing in their composition of narcotic drugs, psychotropic substances or precursors of category 1, taking into account in particular the requirements of the safeguards against their misuse, the procedures for destruction of these measures depending on their type and quantity and the entities obliged to cover the costs associated with the destruction of these measures.

Article. 44a. [application of the freedom of economic activity law] to control the business of the trader referred to in art. 35, 36 and 40, the provisions of Chapter 5 of the Act of 2 July 2004, the freedom of economic activity (Journal of laws of 2015.584, as amended).

Article. 44B. [prohibition of the manufacture, import and marketing of substitutes and new psychoactive substances] 1. It is prohibited to manufacture, import and placing on the market of the territory of the Republic of Poland: 1) substitutes;

2) new psychoactive substances.

2. the competent Minister in charge of health shall determine, by regulation, a list of new psychoactive substances including these substances or groups, taking into account the impact of these substances on the health or the life of the people, or the ability to cause damage.

Article. 44 c [the decision to withhold the product or it is withdrawn from the market] 1. In the case of the manufacture or placing on the market of a product for which there is a reasonable suspicion that it is a means of replacement or a new psychoactive substance, the competent for the place of manufacture or placing on the market of the State Sanitary Inspector orders, by way of a decision, suspend the manufacture of this product or to withdraw it from the market for the time necessary to carry out research to determine whether it is a means of replacement or new psychoactive of not more than 18 months.

2. Main Sanitary Inspector shall make public information on the adoption of the decision referred to in paragraph 1. 1, by the advertisement on your website the personal public information Bulletin the product name, the name of the manufacturer, the type of packaging and its size.

3. in the case of a decision as referred to in paragraph 2. 1, the competent State Sanitary Inspector: 1) security product, for which there is a reasonable suspicion that it is a means of placeholder or the new psychoactive substance;

2) orders to cease doing business in premises or premises for the manufacturing or the introduction of this product on the market for the time necessary to remove the threat, no longer than 3 months.

4. The State health officer competent for the place of manufacture or placing on the market of the product referred to in paragraph 1. 1, prohibits, by decision of its manufacture or marketing, tells its withdrawal from the market, as well as rules on the forfeiture to the Exchequer and destroyed, if this product is a placeholder or a new psychoactive substance.

5. State Sanitary Inspector, which issued the decision referred to in paragraph 1. 4, shall be the competent authority in the case of the destruction of the product which is the subject of this decision. Destruction shall be made collectively. Of the following destruction of the product shall be drawn up of the destruction, which includes: 1) the designation of the competent authority on the destruction;

2) the composition of the Commission appointed to destruction;

3) mark decision giving rise to the damage;

4) type of damaged product, its name and the quantity;

5) about the method of destruction;

6) the designation of the place and time of destruction;

7) the signatures of the members of the Commission.

6. the costs of the proceeding and the tests referred to in paragraph 1. 1, in which it was found that the product under consideration, referred to in paragraph 1. 1, is a placeholder or a new psychoactive substance, and the costs of the destruction of this product shall be borne by the party to the proceedings.

7. the competent state sanitary inspector shall issue a decision fixing the amount of costs referred to in paragraph 1. 6, specifying the 7-day term of payment, counting from the date on which the decision fixing the amount of costs has become final.

8. the security referred to in paragraph 1. 3, paragraph 1, and the enforcement of claims referred to in paragraph 1. 6, followed by in the provisions of the enforcement proceedings in administration.

9. The amount of royalties referred to in paragraph 1. 6, subject to statutory interest, starting from the date on which the period of their payment.

10. Royalties referred to in paragraph 1. 6, shall be barred after 3 years from the date on which the decision setting the charges became final.


11. If the results of the tests referred to in paragraph 1. 1, were found to contain substances other than the new psychoactive substance, but showing the effects on the central nervous system, the person who conducted the test, it shall inform the Team about the outcome of this study.

12. Studies to determine whether the product referred to in paragraph 1. 1, is a placeholder or a new psychoactive substance, shall carry out the entities, including individuals, with the preparation of the technical and scientific, technical and infrastructure, to determine whether the investigational product is a placeholder or a new psychoactive substance, in particular: 1) the origin of the substance of the action on the central nervous system of an identified as a result of the study;

2) mechanism of action of this substance;

3) its pharmacological activity;

4) adverse effects, including the effects of somatic and mental health in humans.

13. the competent Minister in charge of health shall determine, by regulation, a list of the entities referred to in paragraph 1. 12, with a view to ensuring the efficiency of the proceedings by the authorities of the State sanitary inspection.

Article. 44d. [testing, storing and destruction of the product as a means of placeholder or psychoactive] 1. In the case of importation into the territory of the Republic of Poland of the product, for which there is a reasonable suspicion that it may be a means of replacement or a new psychoactive substance, the customs authority takes a shipment of this product for the time necessary to determine whether it is a means of replacement or a new psychoactive substance, not more than 18 months.

2. When it is necessary to carry out the studies referred to in paragraph 1. 1, in order to determine whether it is a means of replacement or a new psychoactive substance shall be entities referred to in article 1. 44 c of paragraph 1. 12.3. If, as a result of studies it is established that the product under consideration is a placeholder or a new psychoactive substance, the customs service applies for judgment his forfeiture to the Exchequer.

4. the forfeiture of product means the placeholder or the new psychoactive substance to the Treasury rules at the request of the customs authority, the Court, in applying the provisions of the code of civil procedure.

5. Product means a replacement or a new psychoactive substance, which the forfeiture has been ordered shall be destroyed.

6. If the importing party is unknown, the product means the placeholder or the new psychoactive substance is destroyed without the presence of the Court to the forfeiture to the Exchequer.

7. The costs of research, storage and destruction of the product as a means of replacement or a new psychoactive substance shall be borne by the importing party. In the case of inability to establish the entity importing product means a replacement or a new psychoactive substance, the costs of research, storage and destruction are financed from the State budget, with part of the remaining available to the boards of customs and customs offices.



Chapter 6 the cultivation of opium poppy and cannabis Article. 45. [restrictions on cultivation of opium poppy and hemp] 1. The cultivation of the opium poppy, excluding poppy niskomorfinowego, may be carried out solely for the needs of the pharmaceutical industry and seed.

2. Cultivation of poppy niskomorfinowego may be carried out only for the purposes of food and seed.

3. Cultivation of fibre hemp may be carried out only for the textile industry, chemical, pulp and paper, food, cosmetic, pharmaceutical, building materials and seed.

4. Cultivation of cannabis other than those mentioned in paragraph 1. 3 is prohibited.

Article. 46. [Conditions of growing and buying a poppy and hemp fibre] 1. The cultivation of the opium poppy may be carried out on the specified surface, in designated areas on the basis of the authorisation for the cultivation, using the basic category seed or certified category within the meaning of the rules of film-coating plus a cultivation contract concluded with authorised Marshal of the pursuit of the activities of the buying-in of poppy seeds.

2. Cultivation of fibre hemp may be carried out on the specified surface, in designated areas on the basis of the authorisation for the cultivation, using the basic category seed or certified category within the meaning of the rules of film-coating plus: 1) cultivation contract concluded with authorised Marshal of the pursuit of the activities of the buying-in of hemp fibre, or 2) the obligation to process hemp fibre plants on its own for the purposes referred to in article 1. paragraph 45. 3, submitted to the Marshal of the competent for the place of cultivation, within 14 days after sowing.

3) (repealed) 4) (repealed) 3. The use of poppy seed or hemp fibre category Basic or certified category within the meaning of the rules of film-coating is confirmed purchase invoice of this seed and label packages of seed of these plants.

4. Activities in the field of intervention: 1) poppy, on the basis of an agreement referred to in paragraph 1. 1, 2) of hemp fibre on the basis of an agreement referred to in paragraph 1. 2 paragraph 1 – can lead entity licensed Marshal responsible for location of cultivation, specifying in particular the scope and purpose of the business.

5. The authorisation referred to in paragraph 1. 4, seems to be by way of a decision, on a proposal which includes: 1) the first name, last name, location of residence and address or name (company), registered office and address of the applicant;

2) taxpayer identification number (Tin) or the identification number in the national register journal of national economy entities (REGON), if it was given, and in the case of a natural person also registration number universal electronic system of population register (PESEL), if it has been rendered;

3) the address of the place of business of buying;

4) about the extent and purpose undertaken activity.

6. the application referred to in paragraph 1. 5, shall be accompanied by: 1) a statement that the applicant has the means of transport or storage, secure anti-theft bags (it), referred to in article 1. 48 para. 1, or 2) (repealed) (3)) the obligation to pass on the request of the Marshal of the information about the scope and purpose of the business.

7. the Marshal shall revoke authorisation in the event of a breach of the terms and conditions referred to in the Act or in the authorization.

8. Regional Council, after consultation with the Minister responsible for health and the Minister responsible for agriculture, shall determine by resolution, the total area for each year under poppy cultivation or hemp fibre and rejonizację of these crops, with a view to the threat of drug abuse, the need for raw materials derived from these crops and the tradition of poppy cultivation and hemp fibre plants in the area.

Article. 47. [the authorisation for the cultivation of poppies or hemp fibre] 1. The authorisation for the cultivation of poppies or hemp fibre plants it seems Mayor (Mayor, Mayor of the city) competent for the place of the position of the crop.

2. The authorisation referred to in paragraph 1. 1, it seems, by a decision, at the request of the containing: 1) the first name, last name, location of residence and address or name (company), registered office and address of the applicant;

2) about a variety of poppy seeds or hemp fibre, the surface of the growing and the number of the standard plot in the records of the land and buildings specified by law, surveying and mapping;

3) (repealed) 4) a declaration by the applicant that has a secure anti-theft bags (it), referred to in article 1. 48 para. 1;

5) a declaration by the applicant that he was not punished for committing a crime referred to in article 1. 63 or 64, and the offences referred to in article 2. 65.3. The authorisation referred to in paragraph 1. 1, specifies: 1) the entity for which they were issued;

2) serial number;

3) variation of the poppy seeds or hemp fibre plants;

4) surface of poppy cultivation or hemp fibre plants;

5) plot number referred to in paragraph 1. 2, paragraph 2, on which will be the cultivation of poppies or hemp fibre plants;

6) expiry date;

7) date of issue of the permit.

3A. the application referred to in paragraph 1. 2, in the case of independent processing hemp fibre plants from their own crops, be accompanied by a commitment to process hemp fibre plants on its own for the purposes referred to in article 1. paragraph 45. 3.3b. The obligation referred to in paragraph 1. 3A, includes: 1) the first name, last name, place of residence and address, or company name, Head Office and address of the manufacturer of hemp fibre plants;

2) taxpayer identification number (Tin) or the identification number in the national register journal of national economy entities (REGON), if it was given, and in the case of a natural person also registration number universal electronic system of population register (PESEL), if it has been rendered;

3) a concise description of the processing plant or place of processing with the equipment;

4) information about the types of products that will be produced by the processing plant.

4. the Mayor (Mayor, Mayor of the city) refuses to issue a permit if the applicant does not give warranties of sound security collection with these crops before using for purposes other than those specified in the Act, and in particular: 1) does not have a secure anti-theft bags (it), referred to in article 1. 48 para. 1, or 2) was punished for committing a crime referred to in article 1. 63 or 64, or 3) was punished for committing the offences referred to in article 2. 65.5. Authorisation shall be withdrawn in the event of a breach of the terms and conditions referred to in the Act or in the authorization.

6. Mayor (Mayor, city President) maintains a register of authorisations.


Article. 48. [the proceedings of the individual parts of the maku] 1. Tea bag (makówkę) seeds obtained from poppy cultivation led to the needs of the pharmaceutical industry, along with adhering to it stem to a length of 7 cm, in full shall be communicated to the operator contract review a Mac, under the conditions laid down in the cultivation contract. Straw preteen music, remaining after the separation of handbags (it) and adjacent to the stems with a length of up to 7 cm, destroys the leading crop in the manner indicated in the cultivation contract.

2. Straw preteen music from poppy cultivation niskomorfinowego destroys the leading crop, at your expense, in the manner indicated in the cultivation contract.

3. Remaining on the poppy crop residues destroyed in place of growing, as a result of the implementation of the appropriate treatment agrotechnicznego, under the conditions laid down in the cultivation contract.

Article. 49. [cultivation of opium poppy and cannabis for Research Centre Cultivars] 1. The provisions of article 4. 45 – 48, with the exception of the provisions relating to the obligation to destroy poppy straw and crop residues poppy, shall not apply to poppy cultivation and cannabis carried out after authorization by the Main pharmaceutical Inspector by the scientific and Research Centre Cultivars, in the framework of the activities of the registered office, as well as by the operator of the plant breeding and using hemp insulation purposes, hereinafter referred to as "the applicant".

2. The authorisation referred to in paragraph 1. 1, it appears on the application containing: 1) the name and address of the applicant;

2) data of the person responsible for ensuring proper control of cultivation and its protection from unauthorized use;

3) data on the location, type and size;

4) data about the planned research, in particular specifying their purpose;

5) about the kind of scientific units;

6) date and signature of the person authorized by the applicant to submit a proposal.

3. the application referred to in paragraph 1. 2, be accompanied by: 1) the opinion of the OU Police right in the place of cultivation, on how to safeguard crops from unauthorized use;

2) statutes of the entity applying for the issue of a residence permit, if applicable.

Article. 50. [supervision of poppy crops or hemp fibre] 1. Supervision of the poppy crops or hemp fibre is exercised by the Mayor (Mayor, Mayor of the city) competent for the place of these crops.

2. In the exercise of supervision of persons authorised by the authority referred to in paragraph 1. 1, are entitled to: 1) views on the land on which they are carried out poppy cultivation or hemp fibre, and a handle to this land by other real estate;

2) control documents entitling to conduct poppy cultivation or hemp fibre plants;

3) require explanations from leading poppy cultivation or hemp fibre.

3. The persons authorized to perform activities referred to in paragraph 1. 2 are obliged to present the authorization issued by the authority exercising supervision.

Article. 51. [Order the destruction of the poppy or cannabis] in case of conduct of poppy cultivation or hemp fibre plants in a manner inconsistent with the article. 46 and 47 Mayor (Mayor, Mayor of the city) seems to warrant destruction of these crops by ploughing, digging out the ground or otherwise, which will ensure the effective implementation of this order, at the expense of the leading crop; suitable for warrant the rigor of immediate enforceability.

Article. 52. [task assigned to the municipality from the scope of the Government] Tasks referred to in article 1. 47, 50 and 51, are performed by the municipality as the task assigned to the scope of Government.



Chapter 6a penalty Article. 52A. [financial penalty for the manufacture or marketing of substitutes] 1. Who produces or markets on the territory of the Republic of Poland means a replacement or a new psychoactive substance, is punishable by a monetary amount from $ 20 000 to 1 0000 0000 $.

2. the penalty referred to in paragraph 1. 1, measures, by way of decision, State Sanitary Inspector the competent for the place of manufacture or placing on the market of substitute or the new psychoactive substance. This decision gives the rigor of immediate enforceability.

3. In determining the amount of the financial penalty, referred to in paragraph 1. 1, the state sanitary inspector shall take account in particular of the amount of produced or marketed substitute or produced or placed on the market of the new psychoactive substance.



Chapter 7 penal legislation Article. 53. [the prohibition of manufacture of narcotic drugs or psychotropic substances] 1. Who, contrary to the provisions of the Act, produces, processes or converts narcotic or psychotropic substances or processes straw preteen music, is liable to imprisonment for 3 years.

2. If the subject of the Act referred to in paragraph 1. 1, is a significant quantity of narcotic drugs, psychotropic substances or poppy straw or this Act was committed in order to achieve financial gain or personal, the offender is subject to a fine and imprisonment for not less than 3 years old.

Article. 54. [prohibition of possession of instruments for the production of narcotic drugs or psychotropic substances] 1. Who produced, has stores, disposes or acquires instruments, if from the circumstances, it appears that they are, or are intended for the illegal manufacture, processing or processing of narcotic drugs or psychotropic substances, shall be subject to fine, restriction of liberty or imprisonment for 2 years.

2. The same penalty shall be subject to who: 1) adapts to the unlawful manufacture, treatment, processing or consumption of narcotic drugs or psychotropic substances, utensils and instruments, even if they were obtained for another purpose, or 2) enters into an agreement with another person to commit an offence referred to in article 1. 53 paragraph 1. 2. Article. 55. [import, export of illegal measures contrary to the provisions of the Act] 1. Who, contrary to the provisions of the Act, shall import, export, transport, intra-Community acquisition or an intra-Community supply of narcotic drugs, psychotropic substances or poppy straw, is subject to a fine and to imprisonment for 5 years.

2. In the case of a minor, the perpetrator shall be subject to a fine, the penalty of restriction of liberty or imprisonment for a year.

3. If the subject of the Act referred to in paragraph 1. 1, is a significant quantity of narcotic drugs, psychotropic substances or poppy straw or this Act was committed in order to achieve financial gain or personal, the offender is subject to a fine and imprisonment for not less than 3 years old.

Article. 56. [Illegal marketing of narcotic, psychotropic or straw preteen music] 1. Who, contrary to the provisions of article. 33-35, art. 37 and article. 40, introduces to the market of narcotic, psychotropic or straw preteen music or participate in this market, is subject to a fine and imprisonment from 6 months to 8 years.

2. In the case of a minor, the perpetrator shall be subject to a fine, the penalty of restriction of liberty or imprisonment for a year.

3. If the subject of the Act referred to in paragraph 1. 1, is a significant quantity of narcotic drugs, psychotropic substances or poppy straw, the offender is subject to a fine and imprisonment from 2 to 12 years.

Article. 57. [Punishment for the preparation of the crime] 1. Who makes preparations for the conduct referred to in article 2. 55 paragraph 1. 1 or article. 56 paragraph 1. 1, shall be subject to a fine, the penalty of restriction of liberty or imprisonment for 2 years.

2. who makes preparations for the conduct referred to in article 2. 55 paragraph 1. 3 or article. 56 paragraph 1. 3, shall be punishable by imprisonment of up to 3 years.

Article. 58. [provision of narcotic or psychotropic substances a minor] 1. Who, contrary to the provisions of the Act, give another person narcotic or psychotropic substance, facilitates or enables their use or urges to use such a measure or substance, shall be punishable by imprisonment of up to 3 years.

2. If the perpetrator of the Act referred to in paragraph 1. 1, give a narcotic drug or psychotropic substance or a minor urges him to use such a measure or matter or provide them in significant quantities to another person, is punishable by imprisonment from 6 months to 8 years.

Article. 59. [Illegal trafficking in narcotic drugs or psychotropic substances] 1. Who, in order to achieve financial gain or personal, give another person narcotic or psychotropic substance, makes it easier to use or urges to use such a measure or substance, shall be punishable by imprisonment from one year to 10 years.

2. If the perpetrator of the Act referred to in paragraph 1. 1, narcotic or psychotropic substances, a minor, makes it easy to use either urges him to use such a measure or substance, shall be punishable by deprivation of liberty for not less than 3 years old.

3. In the case of a minor, the perpetrator shall be subject to a fine, the penalty of restriction of liberty or imprisonment for 2 years.

Article. 60. [Failure of law enforcement authorities of the crime] Who, being the owner or acting on behalf of the Governor or head of catering, entertainment or other service activities, having a reliable message about the Commission of conduct referred to in article 2. 56, 58 or 59 of the establishment or premises, did not notify law enforcement immediately, shall be subject to a fine, the penalty of restriction of liberty or imprisonment for 2 years.


Article. 61. [Illegal storage and marketing of precursors] Who, contrary to the provisions of the Act, regulation 273/2004 or regulation 111/2005, for the illegal manufacture of narcotic or psychotropic substances, produces, processes, transforms, imports, exports, intra-Community acquisition, the intra-Community supply, carries through the territory of the Republic of Poland or the territory of another Member State, acquires, owns, maintains or introduces on the market of precursors, is subject to a fine and to imprisonment for 5 years.

Article. 62. [Prohibited possession of narcotic drugs or psychotropic substances] 1. Who, contrary to the provisions of the Act, has a narcotic or psychotropic substances, is punishable by imprisonment up to 3 years.

2. If the subject of the Act referred to in paragraph 1. 1, is a significant quantity of narcotic drugs or psychotropic substances, the offender shall be liable to imprisonment from one year to 10 years.

3. In the case of a minor, the perpetrator shall be subject to a fine, the penalty of restriction of liberty or imprisonment for a year.

Article. 62A. [adjudicate] if the subject of the Act referred to in article 2. 62 paragraph 1. 1 or 3 are narcotic drugs or psychotropic substances in a quantity slightly, intended for the personal use of an offender, you can release also before the provisions of the initiation of the investigation or the investigation, if the judgment against the offender penalties would be appropriate because of the circumstances of committing one of the acts, as well as the social harmfulness.

Article. 63. [Illegal cultivation of poppy] 1. Who, contrary to the provisions of the Act, grows poppy, excluding poppy niskomorfinowego, hemp, except cannabis fibre, or coca bush, is liable to imprisonment for 3 years.

2. The same penalty shall be subject to, who, contrary to the provisions of the Act, collects milk, opium, poppy straw preteen music, coca leaves, resin or herb of cannabis other than fibrous.

3. If the subject of the Act referred to in paragraph 1. 1, is the cultivation of which can provide a significant amount of poppy straw, coca leaf, resin or herb of cannabis other than fibrous, the offender shall be punishable by imprisonment from 6 months to 8 years.

Article. 64. [Embezzlement of narcotic drugs, psychotropic substances, makowego milk or poppy straw] 1. Who takes to misappropriation, narcotic drugs, psychotropic substances, Royal poppy seed or straw preteen music, is punishable by imprisonment from 3 months to 5 years.

2. If the subject of the Act referred to in paragraph 1. 1, is a significant quantity of narcotic drugs, psychotropic substances, makowego milk or poppy straw, the offender shall be liable to imprisonment from one year to 10 years.

3. The same penalty shall be subject to, who steals the burglary narcotic, psychotropic substances, Royal poppy seed or straw preteen music.

4. In the case of a minor, the perpetrator shall be subject to a fine, the penalty of restriction of liberty or imprisonment for a year.

Article. 65. [cultivation of poppy niskomorfinowego or hemp fibre, contrary to the provisions of the Act] Who, contrary to the provisions of the Act, grows poppy niskomorfinowy or hemp, is punishable by a fine.

Article. 66. [Illegal marketing of precursors] Who, contrary to the provisions of the Act, regulation 273/2004 or regulation 111/2005, produces, processes, transforms, apply, import, export, intra-Community acquisition, the intra-Community supply, carries through the territory of the Republic of Poland or the territory of another Member State, acquires, holds or stores the precursors, is punishable by a fine.

Article. 67. [failure to comply with obligations arising from the provisions of] Who, contrary to the provisions of the Act, regulation 273/2004 or regulation 111/2005, does not fulfill the obligation of keeping records of the manufacture, processing, processing of narcotic drugs, psychotropic substances or precursors and market them, or otherwise affect the provisions relating to the rules for the application of measures, substances or precursors and the marketing of them, is punishable by a fine.

Article. 68. [not allowed advertising] who runs an ad or promotion, contrary to the prohibition set out in article 2. 20(2). 1 or 3, shall be subject to a fine, the penalty of restriction of liberty or imprisonment for a year.

Article. 69. [the application of the provisions of the code of conduct in cases of offences] 1. To rule in cases of acts referred to in article 1. 65-67 follows in the rules in cases of misconduct.

2. In the case of punishment for an offence referred to in article 1. 65 or 66 is the forfeiture of objects of the offense, as well as items derived directly or indirectly from the offence, even if they were not the property of the offender. The Court, ruling the forfeiture of items can be ordered by their destruction. Of the actions of destruction shall be drawn up.

Article. 70. [forfeiture of the subject matter of the crime] 1. [2] in the event of conviction for the offence referred to in article 1. 53 – 61, 63 and 64, you can declare a forfeiture of the subject matter of the crime and the items and tools that were used or were intended to commit fraud, even if it were not the property of the offender.

2. in the event of a conviction for an offence referred to in article 1. 62 and if remission or conditional remission of criminal proceedings is the forfeiture of narcotic drug or psychotropic substance, even if it was not the property of the offender. The Court, ruling the forfeiture of items can be ordered by their destruction. Of the actions of destruction shall be drawn up.

3. Forfeiture did not rule if the narcotic or psychotropic substance, are owned by a third party, and the offender has obtained it by means of crime or offense or entered into their possession in a manner grossly violate the obligations of the employee or the terms of the agreement linking it with the owner of those of narcotic drugs or psychotropic substances.

4. in the event of a conviction for an offence referred to in article 1. 53 – 63, the Court may decide for the purposes of the prevention of and the fight against drug addiction would not be an up to $ 50,000.

5. The provisions of paragraph 1. 4 shall not apply to the offender referred to in article 1. 62 paragraph 1. 1 if it is a person relying party.

Article. 70A. [collection of information on the use by the defendant of narcotic drugs] 1. If there is a reasonable suspicion that the perpetrator is a person relying party or using toxic psychoactive substance, the Court, and in preparatory proceedings the Prosecutor, manages to collect by people that on the principles indicated in the Act certified addiction specialist, information about how to use by the defendant of narcotic drugs, psychotropic substances or substitutes.

2. The Minister of Justice in consultation with the competent Minister for health shall determine, by regulation, the detailed conditions and mode of collection of the information referred to in paragraph 1. 1, the conditions which must be fulfilled by the person entitled to make these steps, and the amount of the lump sum exercise for gathering information, with a view to gathering the relevant data about the person of the accused from the point of view of the possibilities and the appropriateness of the application of the measures provided for in article. 71 and 72.

Article. 71. [suspension of imprisonment] 1. In the event of a conviction of the person relying party for an offense in connection with the use of narcotic or psychotropic substances to imprisonment that conditionally suspended, the court obliges the offender to undergo treatment or rehabilitation in treatment within the meaning of the provisions on medical activities and gives it under the supervision of designated person, institution or association.

2. The Court may order the execution of a suspended prison sentence, if convicted in a period of trying to evade from the obligation referred to in paragraph 1. 1, or allowed to gross violations of the establishment to which he was assigned.

3. in the event of a conviction of the person relying party, taking into account the conditions referred to in paragraph 1. 1, the sentence of imprisonment without suspension, conditional execution, the Court may order the placement of the offender before the penalty in the appropriate entity.

4. Length of stay in treatment does not specify in advance, however, it may not be longer than 2 years. Summary of subject exemption Court on the basis of the results of treatment or rehabilitation. If convicted, not subjected to treatment or rehabilitation or permitted gross violations of the entity, relief may occur also at the request of the subject.

5. The Court shall decide after treatment or rehabilitation, or employment of a penalty involving deprivation of liberty.

6. the competent Minister of health in consultation with the Minister of Justice shall determine, by regulation, the detailed terms and procedures of the treatment or rehabilitation of addicts, referred to in paragraph 1. 1-3, having regard to the welfare of the people relying party.

Article. 72. [Suspension of the proceedings by the Prosecutor] 1. If a person subject to or using toxic psychoactive substance, which was accused of committing a crime in connection with the use of narcotic or psychotropic substance, an offence to imprisonment not exceeding 5 years, treatment, rehabilitation or participation in educational-prophylactic operated by the medicinal or other entity acting on health, the public prosecutor may stay the proceedings until the end of treatment, rehabilitation or participate in the program.

2. following the decision of the proceedings the Prosecutor, having regard to the results of treatment, rehabilitation or participate in educational-prophylactic, decides to continue the investigation or to the Court with a request for a conditional remission procedure.

3. In order to further the investigation the suspect shall be entitled to appeal.


4. In the case referred to in paragraph 1. 2, conditional adjudicate can also apply to the offender an offence not exceeding 5 years in prison. You apply a conditional remission procedure does not preclude the prior criminal record of the offender.

Article. 73. [Suspension of legal proceedings] Recipe article. 72 shall apply mutatis mutandis in the court proceedings until the trial.

Article. 73A. [a break in the execution of the penalty] 1. If you argue in favour of this therapeutic considerations and, consisted of uzależnionemu from of narcotic drugs or psychotropic substances convenes a penalty involving deprivation of liberty for a crime committed in connection with the use of narcotic drugs or psychotropic substances can be given a break in the execution of a sentence of imprisonment, referred to in article 1. 153 § 1 of the criminal code, for treatment or rehabilitation.

2. the condition of granting breaks is to demonstrate by the accused, that he has a guaranteed place of treatment or rehabilitation in appropriate therapeutic entity corresponding to its therapeutic needs.

3. the Prison Court refuses to break in the execution of a sentence of imprisonment for an offence committed in connection with the use of narcotic drugs or psychotropic substances, if convicted, did not previously agree to extend it to appropriate treatment or rehabilitation, referred to in article 1. 117 of the criminal code.

4. the granting of a break in the execution of a sentence of imprisonment is admissible, if the offender to the end of the sentence of deprivation of liberty has remained no more than 2 years.

5. In the case referred to in paragraph 1. 1, the Court of the prison, after the end of treatment or rehabilitation and having regard to the results, manages the further execution of the custodial or conditionally releases a convict with the completion of the rest of the prison sentence, regardless of whether they are satisfied the conditions referred to in article 1. 78 of the criminal code.

Article. 74. [Exclusion from application of the provisions of the criminal code] within the scope of this chapter shall not apply to measures referred to in article 1. 93A § 1 paragraphs 1-3 of the criminal code in respect of the perpetrators, referred to in article 1. 93c item 5 of the criminal code.



Chapter 8 changes in the legislation in force and the transitional and final provisions Article. 75. (omitted) Art. 76. (omitted) Art. 77. (omitted) Art. 78. (omitted) Art. 79. (omitted) Art. 80. (omitted) Art. 81. (omitted) Art. 82. [the validity of the authorisation] Authorisation issued pursuant to art. 23 paragraph 1. 1-3 and 8, art. 25 paragraph 2. 2 and 3 and article. 27 paragraph. 1 and 2 of the Act, referred to in article 1. 90, will remain valid after the entry into force of this Act.

Article. 83. [Authorization for substitution treatment] permit replacement therapy issued pursuant to the provisions of the past become the date of entry into force of the Act, referred to in article 1. 28. Article. 84. [the validity of authorisations for contract review poppy or hemp fibre] 1. Contract review permit opium poppy or cannabis fibrous issued before the date of entry into force of this Act shall cease to be valid on 31 December 2005.

2. where a permit referred to in paragraph 1. 1, no later than 31 December 2005, a request for authorisation to carry on the business of buying poppies or hemp fibre, the authorisation shall be valid until the date on which the decision following examination of an application becomes final.

Article. 85. [Certificates] Certificates of completion of specialist training in the field of drug addiction therapy specialist in the field of addictions and substance abuse therapy instructor obtained before the date of entry into force of this Act become certified addiction specialist and instructor of addiction therapy within the meaning of the provisions of this Act.

Article. 86. [obligation to complete the training] persons employed at the date of entry into force of this Act in the units conducting rehabilitation, who do not have the certificate of specialist drug treatment or drug therapy instructor, are required to complete training referred to in article 1. 27 paragraph. 1, within 5 years after the date of entry into force of the Act.

Article. 87. (omitted) Art. 88. [National Office for counteracting drug addiction after the introduction of the provisions of the Act] 1. National Office for counteracting drug addiction acting under this Act is subrogated in all the rights and obligations of the national Office for Prevention of drug abuse, acting on the basis of article. 3A, paragraph 2. 1 of the Act, referred to in article 1. 90.2. The property operated by the national Office for counteracting drug addiction-based article. 3A, paragraph 2. 1 of the Act, referred to in article 1. 90, becomes the date of entry into force of the law the state your National Bureau for counteracting drug addiction acting under this Act.

3. transfer of rights and property of the National Bureau for counteracting drug addiction, acting on the basis of article. 3A, paragraph 2. 1 of the Act, referred to in article 1. 90, National Bureau for counteracting drug addiction, acting under this Act, is free of charge and is free from taxes and fees.

4. the employees of the National Office for Prevention of drug abuse, acting on the basis of article. 3A, paragraph 2. 1 of the Act, referred to in article 1. 90, on the date of entry into force of the Act become National Bureau for counteracting drug addiction acting under this Act.

Article. 89. [the provisions of previous] regulations issued on the basis of article. 5. 6, art. 9. 4, art. 11 (1). 3, art. 12 paragraph 1. 3, art. 14 paragraph 1. 4, art. 15 paragraph 1. 5, art. 16, art. 22 paragraph 1. 5, art. 23 paragraph 1. 14, art. 24 paragraph. 2, art. 25 paragraph 2. 4, art. 27 paragraph. 6, art. 28 paragraph 1. 4, art. 29. 2, art. 30 paragraph. 2, art. 31 para. 2B. 56 paragraph 1. 6 of the Act, referred to in article 1. 90 of this Act, remain in force until the entry into force of legislation issued on the basis of article. 7 paragraph 1. 5, art. 12 paragraph 1. 4, art. 22 paragraph 1. 3, art. 23 paragraph 1. 4, art. 24 paragraph. 6, art. 27 paragraph. 12 and 13, art. 28 paragraph 1. 7, art. 29. 2, art. 34 para. 5, art. 35 paragraph 1. 10, art. 36 paragraph 1. 3, art. 37 paragraph 2. 12. 38 paragraph 2. 5, art. 40(2). 6, art. 41 paragraph 1. 5, art. 42 paragraph 1. 2, art. 43 paragraph 1. 2 and art. 44 paragraph 1. 9. Article. 90. [the provisions repealed] is repealed law of 24 April 1997 on counteracting drug addiction (Journal of laws of 2003, no. 24, item 198, as amended).

Article. 91. [entry into force] this Act comes into force after 14 days from the date of the notice.



 

 

 

Annex 1. [THE LIST OF NARCOTIC DRUGS]

The annexes to the Act of 29 July 2005.

Annex 1 LIST of NARCOTIC DRUGS 1. Drugs Group and-N Lp.

International names recommended other chemical Markings 1 2 3 1 5-FUR-144 XLR-11 [1-(5-fluoropentylo)-1 h-indole-3-number] (2, 2, 3, 3-tetrametylocyklopropylo) metanon 2 5F-AKB-48 N-(1-adamantylo)-1-(5-fluoropentylo)-1 h-indazol-3-karboksyamid, which is 1-(5-fluoropentylo)-N-tricyklo [3.3.1.133, 7] Deccan-1--YL-1 h-indazol-3-karboksyamid 3-5F-PB-22 ester quinolin-8-ylowy acid 1-(5-fluoropentylo)-1 h-indole-3-carboxylic 4 A-834.735 1-[(tetrahydropiran-4--YL) methyl]-1 h-indole-3-ilo-(2, 2, 3, 3-tetrametylocyklopropylo) metanon 5 AB-001 (1-adamant-1--YL) (1-pentylo-1 h-indole-3-ilo) metanon 6 AB-FUBINACA N-(1-amino-3-methyl-1-oksobutan-2-yl-)-1-(4-fluorobenzylo)-1 h-indazol-3-karboksyamid 7 ACETORFINA 3-O-acetyl-6 , 7, 8, 14-tetrahydro-7α-(1-hydroxy-1-metylobutylo)-6.14-endo-etenooripawina 8 Acetyl-α-methylfentanyl N-[1-(α-metylofenetylo)-4-piperydylo] acetanilide 9 ACETYLOMETADOL 3-acetoksy-6-Dimethylamino-4.4-difenyloheptan 10 AH-7921 3.4-dichloro-N-[(1-dimethylamino) cyclohexyl-methyl] benzamid 11 ALFAACETYLOMETADOL α-3-acetoksy-6-Dimethylamino-4.4-difenyloheptan, which is (3R, 6R)-3-acetoksy-6-Dimethylamino-4.4-difenyloheptan 12 ALFAMEPRODYNA α-3-ethyl-4-phenyl-l-methyl-4-propionyloksypiperydyna, which is the cis-3-ethyl-4-phenyl-l-methyl-4-propionyloksypiperydyna 1 2 3 13 ALFAMETADOL α-6-Dimethylamino-4.4-diphenyl-3-heptanol, which is (3R, 6R)-6-Dimethylamino-4.4-diphenyl-3-heptanol 14 α-Methylfentanyl N-[1-(α-metylofenetylo)-4-piperydylo] propionanilid 15 α-Metylotiofentanyl N-{1-[1-methyl-2-(2-thienyl) ethyl]-4-piperyd -YL} propionanilid 16 ALFAPRODYNA α-4-phenyl-1.3-dimethyl-4-propionyloksypiperydyna, which is the cis-(+/-)-4-phenyl-1.3-dimethyl-4-propionyloksypiperydyna 17 ALFENTANIL N-[1-[2-(4-ethyl-4.5-dihydro-5-oxo-1 h-tetrazol-1-ilo) ethyl]-4-(metoksymetylo)-4-piperidinyl]-N-fenylopropanamid 18 ALLILOPRODYNA 3-allyl-4-phenyl-1-methyl-4-propionyloksypiperydyna 19 AM-694 1-[(5-fluoropentylo)-1 h-indole-3-number] (2-jodofenylo) metanon 20 AM-1220 1-[(1-metylopiperydyn-2--yl) methyl]-1 h-indole-3--YL-(naphthalene-1--YL) metanon 21 AM-1248 1-{[(N-metylopiperydyn-2--yl) methyl]-1 h-indole-3-number} (1-adamantylo) metanon 22 AM-2201 1-[(5-fluoropentylo)-1 h-indole-3-number]-1-naftylometanon 23 AM-2233 1-{[(N-metylopiperydyn-2--yl) methyl]-1 h-indole-3-number}-2-jodobenzylometanon 24 ANILERYDYNA acid ethyl ester 1-p-aminofenetylo-4-phenyl-4-piperydynokarboksylowego 25 APICA SDB-001, 2NE1 N-(1-adamantylo)-1-pentylo-1 h-indole-3-ilokarboksyamid 26 APINACA AKB-48 N-(1-adamantylo)-1-pentylo-1 h-indazol-3-ilokarboksyamid 27 ARGYREIA NERVOSA-live plants or dried, seeds, extracts and extracts of 28


BANISTERIOPSIS CAAPI-live plants or dried, seeds, extracts and extracts 29 BENZETYDYNA acid ethyl ester 1-(2-benzyloksyetylo)-4-phenyl-4-piperydynokarboksylowego 30 BENZYLOMORFINA 3-benzylomorfina, 3-benzyloksy-7.8-didehydro-4.5-α-epoksy-17-metylomorfinan-6α-ol 31 BETACETYLOMETADOL β-3-acetoksy-6-Dimethylamino-4.4-difenyloheptan 32 β-Hydroksyfentanyl N-[1-(β-hydroksyfenetylo)-4-piperydylo] propionanilid 1 2 3 33 β-Hydroxy-3-methylfentanyl N-[1-(β-hydroksyfenetylo)-3-methyl-4-piperydylo]-propionanilid 34 BETAMEPRODYNA β-3-ethyl-4-phenyl-1-methyl-4-propionyloksypiperydyna 35 BETAMETADOL β-6-Dimethylamino-4 , 4-diphenyl-3-heptanol, (3S, 6R)-6-Dimethylamino-4.4-diphenyl-3-heptanol 36 BETAPRODYNA β-4-phenyl-1.3-dimethyl-4-propionyloksypiperydyna 37 BEZYTRAMID 1-(3-cyano-3.3-difenylopropylo)-4-(2-oxo-3-Propionyl-1-benzimidazolinylo) piperidine 38 Butyrfentanyl N-phenyl-N-[1-(2-fenyloetylo) piperydyn-4--YL] butanoamid 39 4-Fluoro-butyrfentanyl N-(4-fluorophenyl)-N-[1-(2-fenyloetylo) piperydyn-4--YL] butanoamid 40 CALEA ZACATECHICHI-live plants or dried, seeds, extracts and extracts of CATHA EDULIS 41-live plants or dried , seeds, extracts and extracts 42 CP 47.497 5-(1,1-dimetyloheptylo)-2-[(1RS secondary, 3SR)-3-hydroksycykloheksylo]-phenol 43 CP 47.497-C6-Homologue 5-(1,1-dimetyloheksylo)-2-[(1RS secondary, 3SR)-3-hydroksycykloheksylo]-phenol 44 CP 47.497-C8-Homologue 5-(1,1-dimetylooktylo)-2-[(1RS secondary, 3SR)-3-hydroksycykloheksylo]-phenol 45 CP 47.497-C9-Homologue 5-(1,1-dimetylononylo)-2-[(1RS secondary, 3SR)-3-hydroksycykloheksylo]-phenol 46 DEKSTROMORAMID Palfium (+)-4-[3,3-diphenyl-2-methyl-4-oxo-4-(1-pirolidynylo)-butyl]-Morpholine , or (+)-1-(2,2-diphenyl-3-methyl-4-morfolinobutyrylo) pirolidyna 47 DEZOMORFINA dihydrodeoksymorfina, or 4.5-epoksy-3-Hydroxy-17-metylomorfinan 48 DIAMPROMID N-[2-N-methyl-(N-fenetyloamino) propyl] propionanilid 49 DIETYLOTIAMBUTEN 3-diethylamino-1.1-bis (2-thienyl) but-1-en 50 DIPHENOXYLATE acid ethyl ester 1-(3-cyano-3.3-difenylopropylo)-4-phenyl-4-piperydynokarboksylowego 51 DIFENOKSYNA acid 1-(3-cyano-3.3-difenylopropylo)-4-phenyl-4-piperydynokarboksylowy 1 2 3 52 DIHYDROETORFINA 7.8-dihydro-7-α-[1-(R)-hydroxy-1-metylobutylo]-6.14-endo-etanotetrahydrooripawina 53 DIHYDROMORFINA 4.5 α-epoksy-17-metylomorfinan-3 , 6α-diol 54 DIMEFEPTANOL 6-Dimethylamino-4.4-diphenyl-3-heptanol 55 DIMENOKSADOL ester of 2-dimetyloaminoetylowy acid 1-Ethoxy-1.1-difenylooctowego 56 DIMETOKAINA Larokaina 4-aminobenzoate 3-(diethylamino)-2.2-dimetylopropylu 57 DIMETYLOTIAMBUTEN 3-dimethylamino-1.1-bis (2-thienyl) but-1-en 58 DIPIPANON 4.4-diphenyl-6-piperidin-3-heptanon 59 DROTEBANOL 3.4-dimethoxy-17-metylomorfinan-6β-diol, at 60 EAM-2201 5-fluoro-JWH-210 4-ethyl-AM-2201 4-etylonaftalen-1--YL-[1-(5-fluoropentylo) indole-3-number] metanon 61 ECHINOPSIS PACHANOI,-live plants or dried , seeds, extracts and extracts 62 EKGONINA acid [1R-(Exo)]-3-Hydroxy-8-methyl-8-azabicyklo [3.2.1] oktano-2-carboxylic acid ethyl ester ETOKSERYDYNA 63 1-[2-(2-hydroksyetoksy) ethyl]-4-phenyl-4-piperydynokarboksylowego 64 ETONITAZEN 1-(2-dietyloaminoetylo)-2-(p-etoksybenzylo)-5-nitrobenzimidazol 65 ETORFINA 6, 7, 8, 14-tetrahydro-7α-(1-hydroxy-1-metylobutylo)-6.14-endoetenooripawina 66 ETYLOMETYLOTIAMBUTEN 3-etylometyloamino-1.1-bis (2-thienyl) but-1-en 67 FENADOKSON 4.4-diphenyl-6-morfolinoheptan-3-68 FENAMPROMID N-(1-methyl-2-piperydynoetylo) propionanilid 69 FENAZOCYNA 2 '-hydroxy-5 9-dimethyl-2-fenetylo-6.7-benzomorfan, 3-fenetylo-1, 2, 3, 4, 5, 6-hexahydro-6.11-dimethyl-2.6-methane-3-benzazocyn-8-ol 70 FENOMORFAN 3-Hydroxy-17-fenetylomorfinan 71 FENOPERYDYNA acid ethyl ester 1-(3-phenyl-3-hydroxypropyl)-4-phenyl-4-piperydynokarboksylowego 72 FENTANYL 1-fenetylo-4-(N-propionyloanilino) piperidine, N-(1-fenetylo-4-piperydylo) propionanilid 1 2 3 73 FLUOROTROPAKOKAINA p-p-4-fluorobenzoiloksytropan FBT fluorobenzoesan-8-methyl-8-azabicyklo [3.2.1] Oct-3-ylu 74 FURETYDYNA ethyl ester 4-phenyl-1-(2-tetrahydrofurfuryloksyetylo)-4-piperydynokarboksylowego 75 HEROIN diacetylomorfina , which is 3.6 α-diacetoksy-7.8-didehydro-4, 5α-epoksy-17-metylomorfinan 76 HU-210 (6aR, 10aR)-9-(hydroxymethyl)-6.6-dimethyl-3-(2-metylooctan-2-yl)-6a, 7,10, 10a-tetrahydrobenzo [c] chromen-1-ol 77 HYDROCODONE dihydrokodeinon, i.e. 4.5 α-epoksy-3-methoxy-17-metylomorfinan-6-78 3-(4-hydroxymethylbenzoyl)-1-pentylindole 3-(4-hydroksymetylobenzoilo)-1-pentyloindol 79 HYDROKSYPETYDYNA ethyl ester of 4-m-hydroxyphenyl-1-methyl-4-piperydynokarboksylowego 80 HYDROMORFINOL 14-hydroxy-7.8-dihydromorfina 81 dihydromorfinon HYDROMORPHONE, which is 4.5 α-epoksy-3-Hydroxy-17-metylomorfinan-6-82 IZOMETADON 6-Dimethylamino-4.4-diphenyl-5-methyl-3-heksanon 83 JWH-007 2-methyl-1-pentylo-3-(1-naftoilo) indole 1-pentylo-2-methyl-3-(1-naftoilo) indole , (2-methyl-1-pentylo-1 h-indole-3-ilo)-naphthalene-1-84 ylometanon JWH-015 (2-methyl-1-propyl-1 h-indole-3-ilo)-1-naftylometanon 85 JWH-018 1-pentylo-3-(1-naftoilo) indole naphthalene-1-YL-(1-pentyloindol-3-ilo) 86 metanon JWH-019 1-heksylo-3-(1-naftoilo) indole naphthalene-1-YL-(1-heksyloindol-3-ilo) metanon 87 JWH-073 1-butyl-3-(1-naftoilo) indole naphthalene-1-YL-(1-butyloindol-3-ilo) metanon 88 JWH-081 (4-metoksynaftalen-1-YL-) (1-pentyloindol-3-ilo) metanon 89 JWH-098 (4-metylonaftalen-1-YL-) (2-methyl-1-pentylo-1 h-indole-3-ilo) metanon 90 JWH-122 1-pentylo-3-(4-methyl-1-naftoilo) indole (4-metylonaftalen-1-YL-) (1-pentylo-1 h-indole-3-ilo) metanon 91 JWH-166 (6-metoksynaftalen-1-YL-) (1-pentylo-1 h-indole-3-ilo) 92 metanon JWH-200 (1-(2- morfolin-4-yloetylo) indole-3-ilo) naphthalene-1-93 ylometanon JWH-201 2-(4-methoxyphenyl)-1-(1-pentylo-1 h-indole-3-ilo) 1 2 3 94 etanon JWH-203 2-(2-chloro-phenyl)-1-(1-pentylo-1 h-indole-3-yl)-etanon 2-(2-chlorophenyl)-1-(1-pentyloindol-3-ilo) etanon 95 JWH-208 (1-propyl-1 h-indole-3-ilo) (4-propylonaftalen-1--YL) metanon 96 JWH-210 (4-etylonaftalen-1-YL-) (1-pentyloindol-3-ilo) metanon 97 JWH-250 1-pentylo-3-(2-metoksyfenyloacetylo) indole 2-(2-methoxyphenyl)-1-(1-pentyloindol-3-ilo) etanon 98 JWH-251 2-(2-methyl phenyl)-1-(1-pentylo-1 h-indole-3-ilo) etanon 99 JWH-302 2-(3-methoxyphenyl)-1-(1-pentyl-1 h-indole-3-ilo) etanon 100 JWH-307 [5-( 2-fluorophenyl)-1-pentylo-1 h-pirol-3-number] naphthalene-1-101 ylometanon JWH-368 [5-(3-fluorophenyl)-1-pentylo-1 h-pirol-3-number]-1-102 naftalenylometanon JWH-398 1-pentylo-3-(4-chloro-1-naftoilo) indole (4-chloronaftalen-1-YL-) (1-pentylo-1 h-indole-3-ilo) metanon 103 Kamfetamina N-methyl-3-fenylobicyklo [2.2.1] adjusted-2-amine 104 KAVA KAVA-live plants or dried, seeds, extracts and extracts of 105 KETOBEMIDON Cliradon 4-(m-hydroxyphenyl)-1-methyl-4-propionylopiperydyna, which is 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperydylo] propan-1-106 KLONITAZEN 2-(p-chlorobenzylo)-1-(2-dietyloaminoetylo)-5-nitrobenzimidazol 107 KODOKSYM O-(karboksymetylo) oxime dihydrokodeinonu 108 KOK LIST 109 COCAINE methyl ester benzoiloekgoniny , which is the acid methyl ester [1R-(Exo, Exo)]-3-benzoiloksy-8-methyl-8-azabicyklo [3.2.1] oktano-2-carboxylic 110 CANNABIS HERB other than fibrous and extracts, tinctures, pharmaceutical, as well as all the other extracts of cannabis other than fibrous 111 LEONOTIS LEONURUS-live plants or dried, seeds, extracts and extracts 112 LEWOMETORFAN (-)-3-methoxy-17-metylomorfinan 1 2 3 113 LEWOMORAMID (-)-4-[2-methyl-4-oxo-3.3-diphenyl-4-(1-pirolidynylo) butyl] Morpholine, which is (-)-1-(2,2-diphenyl-3-methyl-4-morfolinobutyrylo) pirolidyna 114 LEWORFANOL (-)-3-Hydroxy-17-metylomorfinan 115 LEWOTENACYLOMORFAN (-)-3-Hydroxy-17-fenacylomorfinan 116 of POPPY STRAW CONCENTRATE – products resulting from the process for obtaining alkaloids from poppy straw, if these products are placed on the market 117 of POPPY STRAW extracts – other than concentrates, products obtained from poppy straw for the extraction with water or any other solvent, as well as other products obtained by processing milk makowego 118 I-2201 [1-(5-fluoropentylo)-1 h-indole-3-number] (4-methyl-1-naphthyl) metanon 119 METHADONE 6-Dimethylamino-4.4-diphenyl-3-heptanone


120 METHADONE INTERMEDIATE 4-cyano-2-Dimethylamino-4.4-difenylobutan 121 METAZOCYNA 2 '-hydroxy-2, 5.9-trimethyl-6.7-benzomorfan 122 METOPON 5-metylodihydromorfinon, or 4.5-epoksy-3-Hydroxy-5.17-dimetylomorfinan-6-123 METYLODEZORFINA 6-methyl-∆ 6-124 deoksymorfina METYLODIHYDROMORFINA 6-metylodihydromorfina 125 3-Methylfentanyl N-(1-fenetylo-3-methyl-4-piperydylo) propionanilid (cis-and trans-form) 126 3-Metylotiofentanyl N-[3-methyl-1-[2-(2-thienyl) ethyl]-4-piperydylo] propionanilid 127 MIMOSA TENUIFLORA-live plants or dried , seeds, extracts and extracts of MIMOSA TENUIFLORA 128 MIROFINA mirystylobenzylomorfina, 3-benzyloksy-7.8-didehydro-4, 5α-epoksy-6α-mirystoiloksy-17-metylomorfinan tetradekanianu 129 MITRAGYNA SPECIOSA – live plants or dried, seeds, extracts and extracts of 130 MITRAGYNINA acid methyl ester (E)-2-[(2S, 3S)-3-ethyl-8-methoxy-1, 2, 3, 4, 6, 7, 12, 12b-oktahydroindolo [3,2-h] chinolizyn-2--yl]-3-metoksyprop-2-enowego 1 2 3 131 MORAMIDU an INTERMEDIATE acid 1.1-diphenyl-2-methyl-3-morfolinomasłowy 132 MORFERYDYNA ethyl ester of 4-phenyl-1-(2-morfolinoetylo)-4-piperydynokarboksylowego 133 MORPHINE 7.8-didehydro-4 , 5α-epoksy-17-metylomorfinan-3, 6α-diol 134 MORPHINE METYLOBROMEK and other morphine derivatives containing a Quaternary nitrogen 135 MORPHINE-N-oxide N-oxide, 7.8-didehydro-4, 5α-epoksy-17-metylomorfinan-3, 6α-diol 136 MPPP propionate 4-phenyl-1-methyl-4-piperydynolu 137 MT-45 (1-cyclohexyl-4-(1,2-difenyloetylo) piperazyna) 138 NALBUPHINE 3-(cyklobutylometylo) -1,2, 4, 5, 6, 7, 7,-α, 13-oktahydro-4.12-metanobenzofuro [3,2-e] izochinolino-4-α, 7.9-triol 3.6 NIKOMORFINA 139-140 dinikotynoilomorfina NORACYMETADOL α-(+)-3-acetoksy-4.4-diphenyl-6-metyloaminoheptan 141 NORLEWORFANOL (-)-3-hydroksymorfinan 142 NORMETADON 6-Dimethylamino-4 , 4-diphenyl-3-heksanon 143 NORMORFINA demetylomorfina, that is, 7.8-didehydro-4, 5α-epoksymorfinan-3, 6α-diol 144 NORPIPANON 4.4-diphenyl-6-piperidin-3-heksanon 145 NYMPHAEA CAERULEA-live plants or dried, seeds, extracts and extracts of OPIUM and OPIUM tincture 146 147 OXYCODONE Eukodal 14-hydroksydihydrokodeinon, that is, 4.5 α-epoksy-14-hydroxy-3-methoxy-17-metylomorfinan-6-148 OKSYMORFON 14-hydroksydihydromorfinon, that is, 4.5 α-epoksy-3.14-dihydroxy-17-metylomorfinan-6-149 PEGANUM HARMALA-live plants or dried, seeds, extracts and extracts 150 Para-fluorofentanyl 4 '-fluoro-N-(1-fenetylo-4-piperydylo) propionanilid 151 PEPAP acetate 1-fenetylo-4-phenyl-4-piperydynolu acid ethyl ester Dolargan PETHIDINE 152 4-phenyl-1-methyl-4-piperydynokarboksylowego 153 PÓŁPROD PETHIDINE UKT and 4-cyano-4-phenyl-1-metylopiperydyna 1 2 3 154 PETHIDINE INTERMEDIATE B ethyl ester of 4-phenyl-4-piperydynokarboksylowego 155 PETHIDINE INTERMEDIATE C acid 4-phenyl-1-methyl-4-piperydynokarboksylowy 156 PIMINODYNA ethyl ester of 4-phenyl-1-(3-fenyloaminopropylo)-4-piperydynokarboksylowego 157 PIRYTRAMID acid 1-(3-cyano-3.3-difenylopropylo)-4-(1-piperidin)-4-piperydynokarboksylowego, which is the acid 1-(3-cyano-3.3-difenylopropylo)-(1,4-bipiperydyno)-4-carboxylic PROHEPTAZYNA 158 4-phenyl-1 , 3-dimethyl-4-propionyloksyazacykloheptan 159 PROPERYDYNA isopropyl ester of 4-phenyl-1-methyl-4-piperydynokarboksylowego 160 PSYCHOTRIA VIRIDIS-live plants or dried, seeds, extracts and extracts Chacruna 161 QUCHIC BB-22 ester quinolin-8-ylowy acid 1-(cykloheksylometylo)-1 h-indole-3-carboxylic 162 QUPIC PB-22 ester quinolin-8-ylowy acid 1-pentylo-1 h-indole-3-carboxylic RACEMETORFAN 163 (+/-)-3-methoxy-17-metylomorfinan 164 RACEMORAMID (+/-)-4-[3,3-diphenyl-2-methyl-4-oxo-4-(1-pirolidynylo) butyl] Morpholine 165 RACEMORFAN (+/-)-3-Hydroxy-17-metylomorfinan 166 RCS-2 oRCS-4, Ortho-isomer RCS-4 (2-methoxyphenyl) (1-pentylo-1 h-indole-3-ilo) metanon 167 RCS-4 BTM-4 SR-19 ERIC-4 (4-methoxyphenyl) (1-pentylo-1 h-indole-3-ilo) metanon 168 REMIFENTANYL acid methyl ester 1-(2-metoksykarbonyloetylo)-4-(fenylopropionyloamino)-piperidin-4-carboxylic 169 RIVEA CORYMBOSA-live plants or dried, seeds, extracts and extracts 170 SALVIA DIVINORUM-live plants or dried, seeds, extracts and extracts 171 STS-135 N-(1-adamantylo)-1-(5-fluoropentylo)-1 h-indole-3-karboksyamidu 172 SUFENTANIL N-[4-(metoksymetylo)-1-[2-(2-thienyl) ethyl]-4-piperydylo] propionanilid Syntekaina 1 2 3 173 1-(thiophen-2--yl)-2-metyloaminopropan 174 TABERNANTHE IBOGA-live plants or dried , seeds, extracts and extracts 175 TEBAINA 6, 7, 8, 14-tetradehydro-4, 5α-epoksy-3.6-dimethoxy-17-metylomorfinan 176 TEBAKON acetylodihydrokodeinon, that is, 6-acetoksy-6.7-didehydro-4, 5α-epoksy-3-methoxy-17-metylomorfinan 177 Tiofentanyl N-{1-[2-(2-thienyl) ethyl]-4-piperydylo} propionanilid 178 THJ-018 1-naftalenylo (1-pentylo-1 h-indazol-3--YL) methanol 179 TRICHOCEREUS PERUVIANUS-live plants or dried, seeds, extracts and extracts of 180 TRIMEPERYDYNA 4-phenyl-1, 2.5-trimethyl-4-propionyloksypiperydyna 181 TYLIDYNA acid ethyl ester (+)-trans-2-(dimethylamino)-1-phenyl-3-cyklohekseno-1-carboxylic 182-144 (1-pentylo-1 h-indole-3-ilo) (2, 2, 3, 3-tetrametylocyklopropylo) metanon 183 CANNABIS RESIN and :-isomers of narcotic drugs listed in this group, if the existence of such isomers is possible within the chemical marks used, unless such isomers are expressly excluded,-esters and ethers of narcotic drugs listed in this group, if the existence of such esters and ethers is possible, unless they are listed in another group-sole of narcotic drugs listed in this group, including the salts of esters , ethers and isomers, referred to above, if the existence of such salts is possible.

 

2. the narcotic Group II-N international names recommended other chemical Markings 1 2 3 ACETYLODIHYDROKODEINA 6-acetyl-7.8-dihydrokodeina CODEINE 3-O-metylomorfina, that is, 7.8-didehydro-4, 5α-epoksy-3-methoxy-17-metylomorfinan-6α-ol DEXTROPROPOXYPHENE (+)-1.2-diphenyl-4-dimethylamino-3-methyl-2-propionyloksybutan, which is the propionate (2S, 3R)-(+)-1.2-diphenyl-4-dimethylamino-3-methyl-2-butanol DIHYDROKODEINA 7.8-dihydrokodeina ETYLOMORFINA Dionina 3-O-etylomorfina PHOLCODINE morfolinyloetylomorfina, that is, 7.8-didehydro-4, 5α-epoksy-17-methyl-3-(2-morfolinoetoksy) morfinan-6α-ol NIKODYKODYNA 6-nikotynoilo-7.8-dihydrokodeina NIKOKODYNA 6-nikotynoilokodeina NORKODEINA N-demetylokodeina PROPIRAM N-(1-methyl-2-piperydynoetylo)-N-(2-pirydylo) propionamid and :-isomers of narcotic drugs listed in this group, if the existence of such isomers is possible within the chemical marks used, unless the existence of such isomers is expressly excluded,-salts of narcotic drugs listed in this group, including the salts of esters, ethers and isomers, referred to above, if the existence of such salts is possible.

 

3. the narcotic Group III-N 1. Preparations containing in addition to other components of codeine, which amount shall not exceed 50 mg in one dose or concentration does not exceed 1.5% in preparations in the form of a whole.

2. Preparations containing in addition to other components: – ACETYLODIHYDROKODEINĘ – DIHYDROKODEINĘ – ETYLOMORFINĘ – NORKODEINĘ – NIKODYKODYNĘ – NIKOKODYNĘ in the quantity of narcotic does not exceed 100 mg per dose or concentration does not exceed 2.5% in preparations in the form of a whole.

3. Preparations containing one dose maximum of 2.5 mg difenoksylatu calculated in the form of rules and not less than 0.025 mg atropine sulphate in one dose.

4. Preparations containing one dose of not more than 0.5 mg difenoksyny and such quantities of atropine tartrate, which correspond to at least 5% of the dose difenoksyny.

4. the narcotic Group IV-N international names recommended other chemical Markings 1 2 3 ACETORFINA *) 3-O-acetyl-6, 7.8, 14-tetrahydro-7α-(1-hydroxy-1-metylobutylo)-6.14-endo-etenooripawina Acetyl-α-methylfentanyl N-[1-(α-metylofenetylo)-4-piperydylo] acetanilide α-Methylfentanyl N-[1-(α-metylofenetylo)-4-piperydylo] propionanilid 3-Metylotiofentanyl N-[3-methyl-1-[2-(2-thienyl) ethyl]-4-piperydylo] propionanilid β-Hydroksyfentanyl N-[1-(β-hydroksyfenetylo)-4-piperydylo] propionanilid β-Hydroxy-3-methylfentanyl N-[1-(β-hydroksyfenetylo)-3-methyl-4-piperydylo]-propionanilid


DEZOMORFINA dihydrodeoksymorfina, or 4.5-epoksy-3-Hydroxy-17-metylomorfinan ETORFINA *) 6, 7, 8, 14-tetrahydro-7α-(1-hydroxy-1-metylobutylo)-6.14-endo-etenooripawina HEROIN diacetylomorfina, or 3.6 α-diacetoksy-7.8-didehydro-4, 5α-epoksy-17-metylomorfinan KETOBEMIDON Cliradon 4-m-hydroxyphenyl-1-methyl-4-propionylopiperydyna CANNABIS HERB other than fibrous 3-Methylfentanyl N-(1-fenetylo-3-methyl-4-piperydylo) propionanilid (cis-and trans-form) MPPP propionate 4-phenyl-1-methyl-4-piperydynolu Para-fluorofentanyl 4 '-fluoro-N-(1-fenetylo-4-piperydylo) propionanilid PEPAP acetate 1-fenetylo-4-phenyl-4-piperydynolu Tiofentanyl N-[1-[2-(2-thienyl) ethyl]-4-piperydylo] propionanilid CANNABIS RESIN and :-isomers of narcotic drugs listed in this group, if the existence of such isomers is possible within the chemical marks used, unless such isomers are expressly excluded,-esters and ethers of narcotic drugs listed in this group, if the existence of such esters and ethers is possible, unless they are listed in another group-sole of narcotic drugs listed in this group, including the salts of esters , ethers and isomers, referred to above, if the existence of such salts is possible *) can be used in the medicinal uses of animals.

 

Annex 2. [LIST OF PSYCHOTROPIC SUBSTANCES]

Appendix 2 LIST of PSYCHOTROPIC SUBSTANCES 1. Psychotropic substances and groups-P Lp.

International names recommended other chemical Markings 1 2 3 1 2 a, and 2-indanoamina 2.3-dihydro-1 h-inden-2-amine 2 2-AT, 2-aminotetralina 2-amino-1, 2, 3, 4-tetrahydronaftalen 3 2 c-, and 2.5-dimethoxy-4-jodofenetyloamina 4 2 c-T-2 2.5-dimethoxy-4-etylotiofenetyloamina 5 2 c-T-7 2.5-dimethoxy-4-n-propylotiofenetyloamina 6 3F-has 3-fluorometamfetamina, 1-(3-fluorophenyl)-N-metylopropano-2-Amin 7 25B-NBOMe 2-(4-bromo-2.5-dimetoksyfenylo)-N-(2-metoksybenzylo) ethylamine 8 25 c-NBOMe-2 C-C NBOMe 2-(4-chloro-2 , 5-dimetoksyfenylo)-N-(2-metoksybenzylo) ethylamine 9 25 d-NBOMe 2-(2,5-dimethoxy-4-methyl phenyl)-N-(2-metoksybenzylo) ethylamine 10 25E-NBOMe 2-(2,5-dimethoxy-4-ethylphenyl)-N-(2-metoksybenzylo) ethylamine 11 25 g-NBOMe 2-(2,5-dimethoxy-3.4-dimetylofenylo)-N-(2-metoksybenzylo) ethylamine 12 25 h-NBOMe 2-(2,5-dimetoksyfenylo)-N-(2-metoksybenzylo) ethylamine 13 25I-NBOMe 2-(2,5-dimethoxy-4-jodofenylo)-N-(2-metoksybenzylo) ethylamine 25I-NBMD NBMD 14-2 c-and 2-(2,5-dimethoxy-4-jodofenylo)-N-(2,3-metylenodioksybenzylo) ethylamine 15 25N-NBOMe 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-metoksybenzylo) ethylamine 16 BREFEDRON 4-bromometkatynon , 4-BMC, 4-BMAP 1-(4-bromofenylo)-2-metylaminopropan-1-17 BROLAMFETAMINA DOB 4-bromo-2.5-dimetoksyamfetamina, 1-(4-bromo-2.5-dimetoksyfenylo) propan-2-amine 18 BUFEDRON α-(methylamino) butyrophenone 1-phenyl-2-(methylamino) butan-1-19 BUTYLON 1-(1,3-benzodioksyl-5-ilo)-2-(methylamino) butan-1-20 DET N, N-Det 21 DMA (+/–)-2.5-dimethoxy-α-metylofenetyloamina, or 2.5-dimetoksyamfetamina 1 2 3 22 DOET (+/–)-2.5-dimethoxy-4-ethyl-α-metylofenetyloamina, or 2.5-dimethoxy-4-ethylamphetamine 23 DMHP 3-(1,2-dimetyloheptylo)-1-Hydroxy-7 , 8, 9, 10-tetrahydro-6, 6.9-trimethyl-6 h-dibenzo [b, d] piran 24 DMT N, N-DIMETHYLTRYPTAMINE 25 3.4-3.4 DMMC-dimetylometkatynon 1-(3,4-dimetylofenylo)-2-(methylamino) propane-1-26 D2PM Difenyloprolinol diphenyl (pirolidyn-2-yl-) methanol 27 2-DPMP Dezoksypipradrol 2-difenylometylopiperydyna 28 DIBUTYLON 2-dimethylamino-1-(3,4-metylenodioksyfenylo) butan-1-29 Eutylon 1-(1,3-benzodioksol-5--yl)-2-(ethylamino) butan-1-30 ETRYPTAMINA 3-(2-aminobutyl) indole 31 N-ethyl MDA, MDEA (+/–)-N-ethyl-α-methyl-3.4-(metylenodioksy)-phenethylamine 32 N-hydroxy-MDA (+/–)-N-[α-methyl-3 4-(metylenodioksy) fenetylo] hydroksylamina 33 Metkatynon 2-(methylamino)-1-phenyl-1-34 4-Metyloaminoreks (+/–)-cis-2-amino-4-methyl-5-phenyl-2-oksazolina 35 4-MTA α-methyl-4-metylotiofenetyloamina, or 4-metylotioamfetamina 36 ETYLON 2-etylamino-1-(3,4-metylenodioksyfenylo) propan-1-37 4-AcO-DiPT 4-acetoksy-N, N-diizopropylotryptamina 38 4-AcO-DMT 4-acetoksy-N, N-DIMETHYLTRYPTAMINE 39 4-AcO-MET 4-acetoksy-N-ethyl-N-methyltryptamine 40 4-EMC 4-etylometkatynon 2-etylamino-1-p-tolylopropan-1-2-methylamino-1-(4-ethylphenyl) propan-1-1-(4-ethylphenyl)-2-metyloaminopropan-1-41 3-FMC 3-fluorometkatynon 1-(3-fluorophenyl)-2-(methylamino) propane-1-42 4-FMC 4-fluorometkatynon 2-methylamino-1-( 4-fluorophenyl) propan-1-one, that is, 1-(4-fluorophenyl)-2-metyloaminopropan-1-on 43 4-HO-DiPT 4-hydroxy-N, N-diizopropylotryptamina 44 4-HO-MET 4-hydroxy-N-ethyl-N-methyltryptamine 45 5-IT 5-(2-Aminopropyl) indole 46 4-MEC 4-methyl-N-etylokatynon 2-ethylamino-1-(4-methyl-phenyl) propan-1-1 2 3 47 5-MAPB 1-(benzofuran-5--yl)-N-methyl propane-2-amine 48 3-MMC 1-(3-methyl phenyl)-2-(methylamino) propane-1-49 5-MeO-DALT 5-methoxy-N , N-diallilo-tryptamine 50 5-MeO-DMT 5-methoxy-N, N-DIMETHYLTRYPTAMINE 51 5-MeO-MiPT 5-methoxy-N-methyl-N-isopropyltryptamine 52 5-APB 1-(benzofuran-5--yl) propane-2-amine 53 6-APB 1-(benzofuran-6--YL) propane-2-amine 54 6-APDB 1-(2,3-dihydro-1-benzofuran-6--YL) propane-2-amine 55 ETKATYNON N-etylokatynon 2-(ethylamino)-1-phenyl-1-56 ETYCYKLIDYNA PCE N-ethyl-1-fenylocykloheksyloamina 57 FLUOROAMFETAMINA 4-fluoroamfetamina 4-FMP 4-FA 1-(4-fluorophenyl)-2-aminopropan 58 HEKSEDRON 1-phenyl-2-(methylamino)-1-59 Izo-pentedron 1-methylamino-1-phenyl-pentane-2-60 KATYNON (-)-α-aminopropiofenon 61 (+)-LIZERGID LSD , LSD-25 lysergic acid 9.10-didehydro-6-metyloergolino-8β-carboxylic 62 MDMA (+/–)-3.4-metylenodioksy-N, α-dimetylofenetyloamina, or 3.4-methylenedioxy-63 MDPBP 1-(3,4-metylenodioksyfenylo)-2-(pirolidyn-1--YL) butan-1-on 64 MDPPP 1-(3,4-metylenodioksyfenylo)-2-(1-pirolidynylo)-1-propanon 65 MMDA (+/-)-5-methoxy-3.4-metylenodioksy-α-metylofenetyloamina, or 5-methoxy-3.4-metylenodioksyamfetamina 66 Mescaline 3,4,5-trimethoxyphenethylamine 67 MPBP 1-(4-methyl phenyl)-2-(pirolidyn-1--YL) butan-1-68 pMPPP 1-(4-methyl phenyl)-2-(pirolidyn-1--YL)-propan-1-69 Paraheksyl 3-heksylo-1-Hydroxy-7 , 8, 9, 10-tetrahydro-6, 6.9-trimethyl-6 h-dibenzo [b, d] piran 70 PBP Alpha-PBP α-PBP 1-phenyl-2-(pirolidyn-1--YL) butan-1-on the PMA 71 4-methoxy-α-metylofenetyloamina, or para-metoksyamfetamina 72 PMMA 4-methoxy-N, α-dimetylofenetyloamina, which is the p-metoksymetamfetamina 1 2 3 73 Psilocin 4-HO-DMT 3-(2-dimetyloaminoetylo)-4-hydroksyindol 74 MEPHEDRONE 4-metylometkatynon (+/–)-2-methylamino-1-(4-methyl phenyl) propan-1-75 Dimetylokatynon Dimepropion Dimethylpropion METAMFEPRAMONE (RS)-2-dimethylamino-1-fenylpropan-1-76 METEDRON 4-metoksymetkatynon bk-PMMA PMMC 1-(4-methoxyphenyl)-2-(methylamino) propane-1-77 «METYLON 3.4-metylenodioksymetkatynon bk-MDMA 1-(1,3-benzodioksol-5--yl)-2-(methylamino) propan-1-on 78 Metylobufedron 2-(methylamino)-1-(4-methyl phenyl) butan-1-79 Etylobufedron N-etylobufedron NEB 1-phenyl-2-(ethylamino) butan-1-80 NAPHYRONE 0-2482 1-naphthalene-2-yl--2-pirolidyn-1-ylopentan-1-81 PENTEDRON α-metyloaminowalerofenon 1-phenyl-2-(methylamino) pentan-1-82 PENTYLON bk-methyl-K, bk-MBDP 1-(3,4-metylenodioksyfenylo)-2-(methylamino) pentan-1-83 PSILOCYBIN dihydrogen phosphate 3-(2-dimetyloaminoetylo)-4-indolilu 84 Proskalina 2-(3,5-dimethoxy-4-propoksyfenylo) ethylamine 85 RH-34 3-[2-[(2-methoxyphenyl) methylamino] ethyl]-1 h-chinazolino-2 , 4-dion 86 ROLICYKLIDYNA PHP PCPY, 1-(1-fenylocykloheksylo) pirolidyna 87 STP, House 2-amino-1-(2,5-dimethoxy-4-methyl phenyl) propane 88 TENAMFETAMINA MDA 3.4-metylenodioksyamfetamina 89 TENOCYKLIDYNA TCP 1-[1-(2-thienyl) cyclohexyl] piperidine 90 TMA (+/-) -3,4, 5-trimetoksy-α-metylofenetyloamina, that is, 3, 4, 5-trimetoksyamfetamina 91 TMA-2 2, 4, 5-trimetoksyamfetamina 92 TMA-6 2, 4, 6-trimetoksyamfetamina 1-(2, 4, 6-trimetoksyfenylo) propan-2-amine


93 Tetrahydrokannabinole the following isomers and their variants of stereochemiczne: 7, 8, 9, 10-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol,-(9R, 10aR) -8,9, 10, 10a-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol,-(6aR, 9R, 10aR)-6a, 9,10, 10a-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol,-(6aR, 10aR)-6a, 7,10, 10a-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol,-6a, 7, 8, 9-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol,-(6aR, 10aR)-6a, 7, 8, 9, 10, 10a-hexahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol and:-the salts of the substances listed in this group in any case When the existence of such salts is possible,-stereoisomers of substances included in this group, if the existence of such stereoisomers of is possible within the chemical marks used, unless the stereoisomers are expressly excluded.

 

2. Psychotropic Substances of Group II-P Lp.

International names recommended other chemical Markings 1 2 3 1 4-BEC 4-bromoetkatynon 1-(4-bromofenylo)-2-etylaminopropan-1-2 2 c-B 4-bromo-2.5-dimetoksyfenetyloamina 3 2 c-C 2-(4-chlorophenyl-2.5-dimethoxy) ethylamine 4 2 c-D 2-(2,5-dimethoxy-4-methyl phenyl) ethylamine 5 2 c-G 2-(2,5-dimethoxy-3.4-dimetylofenylo) ethylamine 6 2 c-N 2-(2,5-dimethoxy-4-nitrophenyl) ethylamine 7 2 c-P 2-(2,5-dimethoxy-4-propylphenyl) ethylamine 8 3-MeO-PCE 3-Metoksyetycyklidyna N-ethyl-1-(3-methoxyphenyl) cykloheksyloamina 9 3-MeO-PCP 3-Metoksyfencyklidyna 1-[1-(methoxyphenyl) cyclohexyl] piperidine 10

AMPHETAMINE Psychedryna (+/-)-2-amino-1-phenyl 1 2 3 11 AMINEPTYNA acid 7-[(10,11-dihydro-5 h-dibenzo [a, d] cyklohepten-5--yl) amino] heptanoic BZP BENZYLPIPERAZINE 12-1-benzylpiperazine, or 1-benzyl-1.4-diazacykloheksan 13 Dibenzylopiperazyna DEKSAMFETAMINA 14, dibenzylopiperazyna-1.4 DBZP (+)-2-amino-1-phenyl 15 ETYLOFENIDAT 2-phenyl-2-(piperydyn-2--yl) ethyl acetate 16 PHENCYCLIDINE PCP 1-(1-fenylocykloheksylo) piperidine 17 FENETYLINA (+/–)-3.7-dihydro-1.3-dimethyl-7-[2-[(1-methyl-2-fenetylo) amino] ethyl]-1 h-puryno-2 , 6-Dione 18 PHENMETRAZINE 2-phenyl-3-metylomorfolina 19 KETAMINE 2-(2-chlorophenyl)-2-(methylamino)-cyclohexane 20 gamma-hydroxybutyrate GHB acid 4-hydroksybutanowy 21 LEWAMFETAMINA (-)-α-metylofenetyloamina 22 LEWOMETAMFETAMINA (-)-1-N, α-dimetylofenetyloamina 23 4-metyloamfetamina 4-1-(4-methyl phenyl) propane-2-amine, that is, 1-(4-methyl phenyl)-2-aminopropan (4-MA) 24 MBZP 1-benzyl-4-metylopiperazyna 25 mCPP 1-(3-chlorophenyl) piperazyna 26 MEKLOKWALON 3-(o-chlorophenyl)-2-methyl-4 (3 h)-chinazolinon 27 MeOPP pMPP 4 of the IRP, Paraperazyna 1-(4-methoxyphenyl) piperazyna 28 METAKWALON 2-methyl-3-(o-tolilo)-4 (3 h)-chinazolinon 29 METHAMPHETAMINE Methamphetamine racemic (+)-2-methylamino-1-phenyl (+/-)-2-methylamino-1-phenyl METIOPROPAMINA 30 MPA N-methyl-1-(thiophen-2--yl) propan-2-amine 31 MXE METOKSETAMINA 2-(3-methoxyphenyl)-2-(ethylamino) cyclohexanone 32 METHYLPHENIDATE Rytalina acid methyl ester α-phenyl-(2-piperidin)-acetic acid 33 PENTAZOCINE Fortral (2R, 6R, 11R *) -1,2, 3, 4, 5, 6-hexahydro-8-hydroxy-6.11-dimethyl-3-(3-methyl-2-butenylo)-2.6-methane-3-benzazocyna 34 pFPP 4-fluorofenylopiperazyna 1-(4-fluorophenyl) piperazyna 35 SALWINORYNA and 9-acetoksy-2-(furan-3--YL)-6a 10b-dimethyl-4.10-dioksododekahydro-1 h-benzo [f] izochromeno-7-methyl carboxylate 1 2 3 36 SEKOBARBITAL acid 5-allyl-5-(1-metylobutylo) barbituric 37 ∆ 9-tetrahydrocannabinol and its variants stereochemiczne (6aR, 10aR)-6a, 7, 8, 10a-tetrahydro-6, 6.9-trimethyl-3-pentylo-6 h-dibenzo [b, d] piran-1-ol 38 TFMPP 3-trifluorometylofenylopiperazyna 1-[3-(trifluoromethyl) phenyl] piperazyna 39 ZIPEPROL α-(α-metoksybenzylo-4-β-methoxyphenyl)-1-piperazynoetanol, and:-isomers of psychotropic substances listed in this group, if the existence of such isomers is possible within the chemical marks used unless such isomers are expressly excluded,-esters and ethers psychotropic substances listed in this group, if the existence of such esters and ethers is possible, unless they are listed in another group-sole psychotropic substances listed in this group, including the salts of esters, ethers and isomers, referred to above, if the existence of such salts is possible.

 

3. Psychotropic Substances of Group III-P international names recommended other chemical Markings 1 2 3 AMOBARBITAL Amytal acid 5-ethyl-5-izopentylobarbiturowy BUPRENORPHINE 21-cyklopropylo-7-α-[(S)-1-hydroxy-1, 2,2-trimetylopropylo]-6.14-endo-ethane-6, 7, 8, 14-tetrahydrooripawina acid BUTALBITAL 5-allyl-5-izobutylobarbiturowy CYKLOBARBITAL acid 5-(1-cykloheksen-1-YL-)-5-etylobarbiturowy FLUNITRAZEPAM 5-(o-fluorophenyl)-1.3-dihydro-1-methyl-7-nitro-2 h-1.4-benzodiazepine-2-on GLUTETHIMIDE Glimid 3-ethyl-3-phenyl-2.6-dioksopiperydyna KATYNA (+)-treo-2-amino-1-hydroxy-1-phenyl PENTOBARBITAL Nembutal acid 5-ethyl-5-(1-metylobutylo)-barbituric and the salts of the substances listed in this group in any case When the existence of such salts is possible.

 

4. Psychotropic substances Group IV-P Lp.

International names recommended other chemical Markings 1 2 3 1 Alpha-PHP-PHP α 1-phenyl-2-(pirolidyn-1--YL) hexane-1-2 Alpha-the PPP α-PPP 1-phenyl-2-(pirolidyn-1--YL) propan-1-3 Alpha-PVP-PVP α 1-phenyl-2-(pirolidyn-1--YL) pentan-1-4 ALLOBARBITAL 5.5 acid-diallilobarbiturowy 5 ALPRAZOLAM 8-chloro-6-phenyl-1-methyl-4 h-s-triazolo [4,3-a] [1,4] benzodiazepina 6 AMFEPRAMON Dietylopropion 2-diethylamino-1-phenyl-1-propanon 7 AMINOREKS 2-amino-5-phenyl-2-oksazolina 8 BARBITAL Veronalum dietylobarbiturowy BENZFETAMINA 9-5.5 acid N-benzyl-N-α-dimethyl-phenethylamine 10 BROMAZEPAM 7-bromo-1 , 3-dihydro-5-(2-pirydylo)-2 h-1.4-benzodiazepine-2-11 BROTIZOLAM 2-bromo-4-(o-chlorophenyl)-9-methyl-6 h-tieno [3,2-f]-s-triazolo [4,3-a] [1,4] diazepina 12 BUTOBARBITAL acid 5-butyl-5-etylobarbiturowy 13 2 c-E 2.5-dimethoxy-1-etylofenyloetyloamina (2,5-dimethoxy-4-ethylphenyl)-2-aminoetan 14 4-Cl-α-PPP 4-chloro-Alpha-PPP 1-(4-chlorophenyl)-2-(pirolidyn-1--YL) propan-1-15 CHLORDIAZEPOXIDE Elenium 4-oxide-7-chloro-5-phenyl-2-(methylamino)-3 h-1.4-benzodiazepines 16 DELORAZEPAM 7-chloro-5-(o-chlorophenyl)-1.3-dihydro-2 h-1 , 4-benzodiazepine-2-17 DIAZEPAM Relanium 7-chloro-5-phenyl-1.3-dihydro-1-methyl-2 h-1.4-benzodiazepine-2-18 ESTAZOLAM 8-chloro-6-phenyl-4 h-s-triazolo [4,3-a] [1,4] benzodiazepina 19 ETCHLORWYNOL 1-chloro-3-ethyl-1-penten-4-in-3-ol 20 ETYLAMFETAMINA (+/–)-N-ethyl-α-metylofenetyloamina, N-ethylamphetamine 21 ETYNAMAT ester 1-etynylocykloheksylowy acid karbaminowego 22 FENDIMETRAZYNA (+)-3.4-dimethyl-2-fenylomorfolina 23 FENKAMFAMINA (+/–)-N-ethyl-3-fenylobicyklo [2.2.1] adjusted-2-amine 24 PHENOBARBITAL Luminalum acid 5-ethyl-5-fenylobarbiturowy 25 FENPROPOREKS (+/-)-3-[(α-metylofenetylo) amino] propionitryl PHENTERMINE 26 α, α-dimetylofenetyloamina 27 FLUDIAZEPAM 7-chloro-5-(o-fluorophenyl)-1.3-dihydro-1-methyl-2 h-1 , 4-benzodiazepine-2-28 FLURAZEPAM 7-chloro-1-[2-(diethylamino) ethyl]-5-(o-fluorophenyl)-1.3-dihydro-2 h-1.4-benzodiazepine-2-a 1 2 3 29 HALAZEPAM 7-chloro-5-phenyl-1.3-dihydro-1-(2, 2, 2-trifluoroetylo)-2 h-1.4-benzodiazepine-2-30 HALOKSAZOLAM 10-bromo-11b-(o-fluorophenyl) -2,3, 7, 11b-tetrahydrooksazolo [3,2-d] [1,4] benzodiazepine--6 (5 h)-KAMAZEPAM 31, dimetylokarbaminian 7-chloro-5-phenyl-1.3-dihydro-3-Hydroxy-1-methyl-2 h-1.4-benzodiazepine-2-one 32 KETAZOLAM 11-chloro-12b-phenyl-8, 12b-dihydro-2.8-dimethyl-4 h-[1,3]-oxazino-[3,2-d] [1,4] benzodiazepino-4 , 7 (6 h)-Dione 33 CLOBAZAM 7-chloro-5-phenyl-1-methyl-1 h-1.5-benzodiazepino-2, 4 (3 h, 5 h)-Dione KLOKSAZOLAM 34 10-chloro-11b-(o-chlorophenyl) -2,3, 7, 11b-tetrahydrooksazolo-[3,2-d] [1,4] benzodiazepine-6 (5 h)-on 35 CLONAZEPAM Rivotril 5-(o-chlorophenyl)-1.3-dihydro-7-nitro-2 h-1.4-benzodiazepine-2-36 CLORAZEPATE acid 7-chloro-5-phenyl-2.3-dihydro-2-oxo-1 h-1.4-benzodiazepino-3-carboxylic acid 37 KLOTIAZEPAM 5-(o-chlorophenyl)-7-ethyl-1.3-dihydro-1-methyl-2 h-tieno [2,3-e]-1.4-diazepin-2-38 LEFETAMINA SPA


(-)-1-dimethylamino-1.2-difenyloetan, (-)-N, N-dimethyl-1.2-difenyloetyloamina acid ethyl ester ETHYL LOFLAZEPINIAN 39 7-chloro-5-(o-fluorophenyl)-2.3-dihydro-2-oxo-1 h-1.4-benzodiazepino-3-carboxylic 40 LOPRAZOLAM 6-(o-chlorophenyl)-2.4-dihydro-2-[(4-methyl-1-piperazynylo) metyleno]-8-nitro-1 h-imidazo [1,2-a] [1,4] benzodiazepine-1-on 41 LORAZEPAM 7-chloro-5-(o-chlorophenyl)-1.3-dihydro-3-Hydroxy-2 h-1.4-benzodiazepine-2-42 LORMETAZEPAM 7-chloro-5-(o-chlorophenyl)-1.3-dihydro-3-Hydroxy-1-methyl-2 h-1.4-benzodiazepine-2-43 MAZINDOL 5-(p-chlorophenyl)-2.5-dihydro-3R-imidazo [2,1-a]-izoindol-5-ol 44 MDPEA 3.4-metylenodioksyfenyloetyloamina Metylenodioksyfenyloetyloamina homopiperonyloamina 3.4-metylenodioksy-2-phenylethylamine MDPV 1 2 3 45 MDαPVP 1-(MDPK 1.3-benzodioksylo-5-yl)-2-pyrrolidine carboxylic-1-ylpentan-1-on 46 MEDAZEPAM Rudotel 7-chloro-5-phenyl-2.3-dihydro-1-methyl-1 h-1.4-benzodiazepina 47 MEFENOREKS (+/–)-N-(3-chloropropyl)-α-metylofenetyloamina 48 MEPROBAMATE 2.2-di (karbamoiloksymetylo) pentane, or dikarbaminian 2-methyl-2-propyl-1.3-propanediol 49 METYLOFENOBARBITAL Prominalum acid 5-ethyl-5-phenyl-N-metylobarbiturowy 50 METHYPRYLON 3.3-diethyl-5-methyl-2.4-piperydynodion 51 MEZOKARB 3-(α-methyl phenyl)-N-(fenylokarbamoilo)-sydnonimina 52 MIDAZOLAM 8-chloro-6-(o-fluorophenyl)-1-methyl-4 h-imidazo [1,5-a] [1,4] benzodiazepina 53 MMDPEA 5-Methoxy-2-MDPEA (7-methoxy-1 3-benzodioksol-5--yl) ethylamine 54 NIMETAZEPAM 5-phenyl-1.3-dihydro-1-methyl-7-nitro-2 h-1.4-benzodiazepine-2-55 NITRAZEPAM 5-phenyl-1.3-dihydro-7-nitro-2 h-1.4-benzodiazepine-2-56 NORDAZEPAM 7-chloro-5-phenyl-1.3-dihydro-2 h-1.4-benzodiazepine-2-57 OXAZEPAM 7-chloro-5-phenyl-1.3-dihydro-3-Hydroxy-2 h-1.4-benzodiazepine-2-58 OKSAZOLAM 10-chloro-11b-phenyl-2, 3.7, 11b-tetrahydro-2-metylooksazolo [3,2-d] [1,4] benzodiazepine-6 (5 h)-on 59 PEMOLINE 2-amino-5-phenyl-2-oksazolin-4-or 5-phenyl-2-imino-4-oksazolidynon 60 PINAZEPAM 7-chloro-5-phenyl-1.3-dihydro-1-(2-Propionyl)-2 h-1 , 4-benzodiazepine-2-61 PIPRADROL 1.1-diphenyl-1-(2-piperydylo) methanol 62 PIROWALERON (+/-)-1-(4-methyl phenyl)-2-(1-pirolidynylo)-1-pentanon 63 PRAZEPAM 7-chloro-1-(cyklopropylometylo)-5-phenyl-1.3-dihydro-2 h-1.4-benzodiazepine-2-64 SEKBUTABARBITAL acid 5-sec-butyl-5-etylobarbiturowy 65 TAPENTADOL 3-[3-(dimethylamino)-1-ethyl-2-metylopropylo] phenol 66 TEMAZEPAM Signopam 7-chloro-5-phenyl-1.3-dihydro-3-Hydroxy-1-methyl-2 h-1.4-benzodiazepine-2-a 1 2 3 67 TETRAZEPAM 7-chloro-5-(cykloheksen-1--YL)-1.3-dihydro-1-methyl-2 h-1 , 4-benzodiazepine-2-68 TRIAZOLAM 8-chloro-6-(o-chlorophenyl)-1-methyl-4 h-s-triazolo [4,3-a] [1,4] benzodiazepina 69 WINYLBITAL acid 5-(1-metylobutylo)-5-winylobarbiturowy 70 ZALEPLON N-(3-(3-cyjanopirazolo [1,5-a] pirymidyn-7--YL) phenyl)-N-etylacetamid 71 ZOLPIDEM N, N, 6-trimethyl-2-(4-methyl phenyl) imidazo [1,2-a] pyridine-3-acetamide 72 ZOPICLONE 4-metylpiperazyno-1-karboksylan6-(5-chloropirydyn-2-yl-)-7-oxo-6.7-dihydro-5 h-pyrrole [3,4-b] irazyn-5-YLE and the salts of the substances listed in this group in any case When the existence of such salts is possible.

 

[1] Article. 27 paragraph. Article 2 point 3 is added to be fixed by the article. 41 of the Act of September 25, 2015. amending the Act on freedom of economic activity and certain other laws (OJ. 1893). The change came into force 19 may 2016.

[2] on the basis of the judgment of the Constitutional Court of 28 October 2015 (OJ. 2014) art. 70 paragraph 1. 1, in so far as it permits the confiscation of the subject to commit one of the offences listed in that provision, which is not the property of the offender, if the owner or other person entitled, despite the caution required in the circumstances, did not provide for and could not have foreseen that it could be used to commit any of these offences, is incompatible with article 2. 42 paragraph 1. 1 in connection with article. 2 and art. 64 paragraph 1. 1 and 3 in conjunction with article. 31 para. 3 of the Constitution. Article. 70 paragraph 1. 1 in ww. the field has lost the power of 2 December, 2015.

Related Laws

2008 Drug Law